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Abstract 
 
Introduction:  It has been reported that HNPCC colorectal carcinomas 
demonstrate a better prognosis compared to sporadic carcinoma, however the 
exact mechanism for this is still uncertain.  It is possible that tumour morphology, 
location and cell cycle markers may be indicators of the underlying molecular 
mechanism.  In a resource limited setting these factors may help to stratify which 
cases need further molecular testing and genetic counselling.  
Aims and objectives: To characterise the macroscopic and microscopic 
pathology in three cohorts of patients.  The cohorts include (1) patients with 
CRCs that are < 50 years and mutation negative, (2) < 50 years and DNA 
mismatch repair gene mutation positive and (3) more than 50 years (sporadic).  
To investigate the immunoexpression of the cell cycle regulators (p21, p27, p53, 
c-myc, cyclin D1 and cyclin E) and MMP-7 in each cohort. 
To compare the immunoexpression of each marker between cohorts. 
To correlate the immunoexpression of each marker with tumour type, stage and 
grade. 
Materials and methods:  In total, 17 mutation negative, 15 mutation positive 
and 28 sporadic adenocarcinoma resection cases were available for study.  The 
histopathological features of all cases were reviewed.  The cases were stained 
with antibodies against p21, p27, cyclin D1, cyclin E, p53, c-myc MMP-7, 
MLH1, MSH2 and MSH6.  Results were considered statistically significant if P < 
0.05, and P<0.017 if 3 pairs of medians were compared. 
Results:  The mutation positive tumours were more frequently right sided 
tumours and showed mucinous differentiation, tumour infiltrating lymphocytes 
and an expanding border.  The sporadic and mutation negative cohorts showed 
similar morphology.  In the sporadic cohort, the five tumours that were MLH1 
negative demonstrated morphological features of MSI-H tumours.  
MLH1 mutations were the commonest.  MLH1 immunoexpression was lost in the 
mutation positive tumours and was statistically significant when compared to the 
other two cohorts.  There was no statistical significance among the three cohorts 
for MSH2 and MSH6 immunoexpression.  
There was no statistically significant difference in immunoexpression for p21, 
p27, p53 and MMP-7 among the three cohorts.  Furthermore, there was no 
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association with tumour type and stage.  Cyclin D1 expression was increased in 
the mutation positive cohort and was statistically significant when compared to 
the mutation negative cohort only.  Cyclin E expression was also increased in the 
mutation positive cohort and was statistically significant when compared to the 
sporadic cohort only.   
Conclusion:  The morphological features of colorectal carcinomas can be helpful 
in identifying MSI-H tumours and cases requiring further molecular studies. The 
cell cycle marker expressions did not explain the expected differences in patient 
outcome and prognosis.  The mutation negative cohort in our population 
continues to remain enigmatic and further testing at the molecular level is 
required, that may reveal another novel pathway of colorectal carcinogenesis or 
other novel mutations in mismatch repair genes. 
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 CHAPTER 1 
 
1. INTRODUCTION AND LITERATURE REVIEW 
1.1 Introduction 
Colorectal carcinoma (CRC) in South Africa has been increasing over the past 
decade, and was recently ranked as one of the top five cancers, fifth amongst 
males and third amongst females (1). Worldwide, CRC is a major cause of 
morbidity and mortality.  
 
The main pathways that are implicated in carcinogenesis include the 
chromosomal instability pathway (CIN), microsatellite instability pathway (MSI), 
and the CpG island methylator phenotype (CIMP) pathway. In recent times, the 
serrated neoplastic pathway showing some overlapping features with the above 
pathways has been described. Finally, microRNAs are emerging as important 
adjuncts in the pathway of carcinogenesis. It is known that HNPCC positive 
patients (part of the MSI pathway) have a more favourable prognosis when 
compared with sporadic CRC. 
 
Pathological features, tumour site and cell biomarkers are helpful in guiding the 
pathologist to the underlying molecular aberrations. This may aid the pathologist 
in choosing the appropriate molecular diagnostic tests, especially in a resource 
limited setting. In addition, the appropriate patients may be referred for further 
genetic counselling and testing. 
 
This study investigated cell cycle regulators, mismatch repair proteins and matrix 
metalloproteinase 7 (MMP-7) together with morphology in three cohorts of 
patients. The cohorts included patients older than 50 years with sporadic CRC, 
patients younger than 50 years with CRCs that are mutation positive for one of 
the mismatch repair (MMR) genes and patients younger than 50 years with CRCs 
that are mutation negative for MMR genes.  The study was conducted to 
determine possible differences in expression of the markers mentioned above in 
correlation with the three patient cohorts and pathological features, to help further 
1 
 
understand the  progression of colorectal carcinoma and to elucidate possible 
mechanisms for the differences in behaviour of CRC in HNPCC. 
 
1.2  Epidemiology 
1.2.1  Incidence 
CRC is the commonest type of gastrointestinal tract (GIT) cancer and the lifetime 
risk of developing CRC is 1 in 17 for men and 1 in 26 for women (2). It accounts 
for 9% of all cancers, with the highest incidence seen in Australia, New Zealand, 
Canada, parts of Europe and the USA.  The countries that are low risk include 
India, China, parts of Africa and South America. Therefore, it is mainly a disease 
of developed countries which contribute 63% of all cases. However, the incidence 
rates may be biased as there may be a high degree of underreporting in 
developing countries (2, 3). The crude incidence in Sub-Saharan Africa was found 
to be 4.04 per 100 000 population for both sexes, with South Africa having the 
highest rates (4).    
 
Interestingly, in some regions like the USA, Northern and Western Europe, the 
incidence rates have been stabilising and declining. This is due to screening 
programmes that detect precancerous polyps (3). 
 
1.2.2   Mortality rates and trends 
The worldwide mortality due to CRC is approximately half that of the incidence, 
with just over 1 million new cases recorded in 2002, and 530 000 deaths due to 
CRC.  This accounts for ~8% of all cancer related deaths.  It is the fourth most 
common cause of cancer related deaths worldwide. Mortality rates have declined 
in North America, New Zealand, Australia and Western Europe (2, 3).  
 
1.2.3  Non-modifiable risk factors 
1.2.3.1 Age 
The vast majority, 90% of CRCs occur after 50 years of age.  The incidence rate 
increases after 40 years, rising sharply after 50.  The rates are also increasing 
among younger persons (3).  
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1.2.3.2 History of adenomatous polyps 
Adenomas are neoplastic proliferations of glandular epithelium that display 
dysplastic morphology.  In the USA, the lifetime risk of developing an adenoma 
is 19% in the general population (3). The prevalence of these lesions in the USA 
is approximately 25% by age 50 years and 60% by age 70 years (5).  An 
individual with a history of adenomas is at a higher risk of developing CRC than 
an individual without a history of adenomas. 
 
1.2.3.3 History of Inflammatory Bowel Disease 
Crohn’s disease and ulcerative colitis increase an individual’s overall risk of 
developing CRC. The relative risk of CRC in both these diseases has been 
estimated to be between 4-to 20-fold (2, 3). 
 
1.2.3.4 Family history of CRC or adenomatous polyps 
Individuals with a history of CRC or adenomatous polyps in one or more first-
degree relatives are at increased risk.  The vast majority of CRC cases occur 
without a family history, with only 20% (excludes inherited genetic risk) of 
people with CRC having other family members affected by the disease.  The 
increased risk may be due to inherited genes or shared environmental factors (2). 
 
1.2.3.5 Inherited genetic risk 
Approximately 5% of CRCs are due to inherited mutations, which are highly 
penetrant single gene mutations (3, 6). The most common are familial 
adenomatous polyposis (FAP) and hereditary non-polyposis colorectal cancer 
(HNPCC), also known as Lynch syndrome.  
 
1.2.4  Environmental risk factors 
1.2.4.1 Nutritional Factors 
Diets high in animal fat and meat, and low in dietary fibre have been implicated 
in CRC. The high dietary fat has been linked to the growth of intestinal bacterial 
flora which degrade bile salts to carcinogenic compounds (3).  The mechanisms 
for the association with meats include haem iron in red meat and cooking at high 
temperatures resulting in heterocyclic amines and polycyclic aromatic 
hydrocarbons. In addition, differences in dietary fibre account for geographic 
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differences in CRC.  Increased fibre increases faecal bulk and decreases the 
transit time (3). 
 
1.2.4.2 Lifestyle factors and Obesity 
Lack of exercise and obesity are contributing factors in about 25 to 30% of CRC.  
The carcinogens found in cigarettes increase cancer growth in the colon and 
rectum.  Regular alcohol consumption is also a factor in the development of CRC, 
especially in younger patients (3). 
 
1.3  Molecular pathways in CRC 
Fearon and Vogelstein put forward the first model for colorectal carcinoma more 
than 20 years ago (7).  The sequential pathway outlined four steps: 
1. APC gene inactivation  adenoma 
2. KRAS mutations  promotes adenoma growth 
3. Alterations of chromosome 18q  progression 
4. p53 inactivation  triggers final transition to carcinoma 
Colorectal cancer encompasses a complex disease process, and new findings 
require further refinement on this initial model.  Four distinct molecular pathways 
have been identified, reflecting different phenotypes.  There is dysregulation of 
cell metabolism, proliferation, differentiation, survival and apoptosis secondary to 
genetic and epigenetic alterations (8, 9).   
 
The four pathways are the chromosomal instability (CIN) pathway, microsatellite 
instability (MSI) pathway, the CpG island methylator phenotype (CIMP) pathway 
and the alternative serrated neoplastic pathway (Figure 1). Besides genomic 
instability, other molecular changes involve microRNAs, epigenetic factors, 
growth factors and epithelial-mesenchymal transitions (9).  The latter two are 
mainly responsible for metastases.  The pathways are not exclusive, and some 
tumours can exhibit more than one pathway.  
 
1.3.1  CIN Pathway 
This pathway, also known as the suppressor pathway, is the most common, 
ranging from 50-85% of sporadic cancers according to recent literature (9).  It is 
characterised by gains and/or losses of whole or portions of chromosomes 
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resulting in karyotypic variability.  It results from defects in chromosome 
segregation and microtubule dysfunction, with subsequent aneuploidy (imbalance 
in chromosome number), telomere dysfunction, telomerase overexpression, or 
defects in the DNA damage response mechanisms (8, 9).  The effect is 
aneuploidy, genomic amplifications and high frequency loss of heterozygosity 
(LOH).  Broad amplifications have been identified on chromosomes 7, 8q, 13q, 
20 and X.  Broad deletions have been identified on 1, 4, 5, 8p, 14q, 15q, 17p, 18, 
20p and 22q (8).  Chromosomes 1, 5, 8, 17 and 18 account for between 46-78% of 
allelic loss (8).  Focal gains and losses have been identified in regions harbouring 
important genes e.g. MYC, VEGF, PTEN and others.  The net effect is mutations 
in proto-oncogenes and tumour suppressor genes (TSG). KRAS and APC genes 
are the most common genetic alterations in CRC (8). 
 
 
 
 
 
 
 
 
Figure 1: Molecular events in CRC 
 
1.3.1.1 KRAS oncogene 
The RAS-RAF-MAPK pathway activates transcription factors that express 
proteins with a role in cellular proliferation, differentiation and survival (9).  The 
RAS family is composed of three members KRAS, HRAS and NRAS (5).  KRAS 
alterations, which are implicated in many human cancers, are seen in 30-60% of 
CRCs and large adenomas (8).  The gene product is a 21 kDa membrane bound 
protein that is activated in response to extracellular signals.  Single nucleotide 
point mutations are usually found which lock the protein in its active form due to 
impaired GTPase activity.  The downstream targets include Bcl2, H2AFZ, 
CIMP Pathway MSI Pathway CIN Pathway 
Molecular Events in CRC 
MicroRNAs 
Epithelial-
Mesenchymal 
transition 
Epigenetic Changes Serrated Neoplastic 
pathway 
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RAP1B, TBX19, E2F4 and MMP1.  Mutations are usually seen at codons 12 (82-
87%), 13 (13-18%) and 61 (% unknown) in human cancers (9). 
 
1.3.1.2  Loss of 5q allele 
Allelic loss of chromosome 5q is seen in 20-50% of sporadic CRCs.  The two 
important genes located on 5q are APC and the mutated in colorectal cancer 
(MCC) (8, 9).  
 
Mutations of APC, the “gatekeeper” of cellular proliferation, have the same 
frequency in very small adenomas as in advanced carcinomas and are even found 
in the earliest lesions composed of a few dysplastic crypts (9).  Hence, it suggests 
that APC mutations are a rate-limiting event in carcinogenesis.  In addition, 
biallelic APC gene defects are needed to promote tumour development 
(Knudson’s two hit hypothesis) (5).  
 
1.3.1.3  APC and the β-catenin-dependent Wnt signalling pathway 
The APC gene encodes a protein that regulates cell-cell adhesion, cell migration, 
chromosomal segregation and apoptosis in colonic crypts.  It is a negative 
regulator of β-catenin, by inducing its degradation. 
 
In the Wnt pathway, in the absence of Wnt ligand signalling, APC binds to the 
scaffold protein Axin, followed by phosphorylation by casein kinase 1 alpha 
(CK1a) and glycogen synthase kinase 3β (GSK3β) (Figure 2).  The net effect is 
ubiquitination and degradation of β-catenin (8, 10).   
 
In the presence of Wnt signalling, the Wnt ligand binds to a complex of Frizzled 
(Fz) proteins and a member of the low-density lipoprotein receptor-related protein 
family (e.g. LRP5 or LRP6), resulting in inhibitory effects on GSK3β and Axin 
(Figure 2).  This is also aided by the action of dishevelled (Dvl).  The net result is 
stabilisation of the β-catenin pool, accumulating in the cytoplasm and eventually 
binding with DNA-binding proteins TCF/LEF (T cell factor/lymphoid enhancer 
family) (5, 10).  Wnt target genes include proto-oncogenes such as c-myc and 
cyclin D1 (CCND1), membrane factors such as matrix metalloproteinase 7 
(MMP-7)/Matrilysin, membrane type 1 MMP-1, laminin-5 gamma 2 chain, 
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CD44, angiogenic factors, apoptotic factors, growth factors such as FGF20 and 
FGF9 (5).  In addition, Wnt feedback regulators (e.g. Axin2, Wnt inhibitory 
factor) are also affected.  Therefore, when both alleles of the APC gene are 
inactivated, the process mimics activation of the Wnt pathway. 
 
Mutations in other canonical Wnt pathway components, include β-catenin 
mutations (CTNNB1 gene), which render it resistant to degradation, mutations in 
Axin1/Axin2 and mutations involving TCF4 (5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Model of APC and β-catenin function: Binding of Wnt to Frizzled (Fz) 
receptor activates Dishevelled (Dvl) and blocks the destruction complex formed 
by Axin. In the absence of Wnt, the axin/conductin complex phosphorylates β-
catenin by GSK3β and CK1a, resulting in β-catenin being degraded in 
proteasomes. 
 
1.3.1.4  MCC gene 
The MCC gene, located on 5q21, is commonly inactivated through promoter 
hypermethylation.  The protein product is a cell cycle regulator that induces cell 
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cycle arrest following DNA damage.  A recent study also suggested an inhibitory 
function on Wnt/β-catenin signal transduction (8). 
 
1.3.1.5  Loss of 8p allele 
In over 50% of CRCs, allelic loss of 8p has been identified.  It is thought that 
TSGs are found in these regions of deletions.  Loss of locus 8p21-22 also 
increases susceptibility for metastases (8).  
 
1.3.1.6  Loss of 17p allele 
This segmental loss is seen in 75% of CRCs but not in adenomas, suggesting a 
late event in CRC carcinogenesis (5, 8).  It houses the p53 gene that is responsible 
for cell cycle arrest, apoptosis, senescence, autophagy and cellular metabolism.  
This TSG will be discussed further below. 
 
1.3.1.7  Loss of 18q allele 
Loss of heterozygosity of 18q is seen in approximately 70% of CRCs, 
approximately 50% of large adenomas and fewer than 10% of small early 
adenomas.  A number of TSGs are found in the long arm of chromosome 18. 
These include Cables, Deleted in Colorectal Cancer (DCC), Smad2 and Smad4. 
The Cables protein is involved with regulation of the cell cycle and interacts with 
CDK2, CDK3 and CDK5.  DCC codes for an immunoglobulin superfamily 
protein (190kda), that plays a role in cell adhesion, migration and induces 
apoptosis in the absence of its ligand netrin-I.  The Smad proteins are 
transcription factors involved in the transforming growth factor β pathway, and 
target genes include c-myc, CBFA1, FLRF and furin.  In addition, these proteins 
downregulate claudin1, in a TGF-β independent manner, which is upregulated in 
metastatic lesions (9). 
 
1.3.2 Microsatellite instability (MSI) pathway 
This pathway first described in the background of HNPCC is seen in 
approximately 15-20% of sporadic CRCs (11, 12).  Microsatellites are short 
repeat nucleotide sequences (1-4 bp in length) that are spread out over the entire 
genome.  These areas in the genome are prone to reading errors and the cell has in 
place, the DNA mismatch repair (MMR) system that detects and repairs base pair 
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mismatches and insertion/deletion loops (IDLs) during replication.  IDLs are 
functionally equivalent as an insertion on one strand which results in the same 
effect as a deletion of the same number of nucleotides on the other strand (13). 
Inactivation of the DNA MMR system results in microsatellites becoming 
unstable when they become abnormally long or short due to gains or losses of 
repeat units.  This inactivation may be genetic (e.g. Lynch syndrome) or acquired.  
Proto-oncogenes and tumour suppressor genes (TSGs) that contain repetitive 
DNA sequences are the major targets as loss of MMR proteins mediates an 
increase in mutation rate that produces a ‘mutator phenotype’.  Genes affected by 
MSI include TGFβRII, EGFR, BAX, regulators of proliferation (e.g. GFB1, Axin-
2, CDX, GRB1), the cell cycle or apoptosis (e.g. BCL10, PTEN, caspase-5, FAS) 
and DNA repair.  The genes that do not appear to be affected include p53 and 
KRAS (9). 
 
The MMR system includes the following genes, MLH1, MLH2, MLH3, MSH2, 
MSH3, MSH4, MSH5, MSH6, PMS1, PMS2, and Exo1.  Two heterodimeric 
complexes have been described, the MutS- and MutL-related proteins.  The MutL 
complex contains MLH1 protein plus one of the other binding partners (PMS2, 
MLH3, PMS1 or MLH2).  Similarly, MutS contains the MSH2 protein plus one 
of the other binding partners usually MSH6 or MSH3.  These complexes together 
with replication factors and other proteins allow excision and resynthesis of the 
affected DNA to proceed.  MSH2 and MLH1 are common components of these 
complexes, therefore loss of either one will result in no MMR activity, whereas 
loss of one of the partner components (e.g. MSH6) will only diminish activity of 
the MMR pathway.  This might explain why most of the Lynch syndrome patients 
have germline mutations in either MSH2 or MLH1 (~90%) (13, 14). 
 
The International Workshop, held in Bethesda on Microsatellite Instability 
sponsored by the National Cancer Institute in 1997, recommended a panel of five 
microsatellite loci for the identification of MSI (15).  This involves extraction of 
tumour DNA and amplification of the microsatellite loci using polymerase chain 
reaction (PCR).  The PCR products are then compared to normal tissue or blood 
and using a fluorescent DNA analyser MSI can be identified.  
Based on the above test MSI can be divided into 3 cohorts: 
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1. Microsatellite stable (MSS) – no evidence of MSI 
2. MSI found at high frequency (MSI-H) - Defined as instability in 2 or more 
markers. 
3. MSI found at low frequency (MSI-L) – Instability in one marker. 
Immunohistochemical staining can be used to detect the MMR proteins. 
Abnormal MMR protein expression can be detected in two patterns, either 
complete loss of expression or patchy weak expression (13).  Complete loss of 
expression may be due to no expression of the protein or expression of a truncated 
protein to which the antibody does not bind.  Patchy weak staining may be seen 
when a prematurely truncated but variably stable protein is generated, or a protein 
with alterations in the epitope recognized by the antibody.  The changes in 
expression of MMR proteins follow the pattern of their heterodimeric complex 
formation, e.g. abnormal PMS2 expression is associated with abnormal MLH1 
expression (13, 16). 
 
MSI-H tumours tend to have a distinct phenotype characterised by location and 
histopathological features.  These tumours are usually located proximal to the 
splenic flexure, mainly in the right colon.  Histologically, these tumours have 
increased lymphocytic infiltration, mucinous histology and poor differentiation 
with medullary growth pattern (17). 
 
1.3.2.1  MSI in sporadic vs hereditary CRC 
Mutations or deletions or epigenetic silencing of both copies of one of the MMR 
genes results in loss of function.  MSI is the hallmark of HNPCC (Lynch 
syndrome), where one germline mutation is inherited and subsequent inactivation 
of the wild-type allele by mutation, or loss or epigenetic inactivation (second hit), 
with no expression of the functional protein.  Approximately 15-20% of sporadic 
CRCs are due to somatically acquired changes in the MMR proteins, and is 
almost entirely caused by hypermethylation of the MLH1 promoter region that 
results in gene silencing.  A high frequency of MSI is found in adenomas of 
HNPCC and is only rarely found in sporadic adenomas (13, 17). 
 
BRAFV600E mutations are seen frequently in sporadic MSI-H CRC but not in 
HNPCC.  The RAS-RAF-MAPK pathway activates transcription factors that 
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express proteins with roles in cell differentiation and proliferation.  The RAF 
family of molecules includes ARAF, RAF1 and BRAF.  Similar to KRAS 
mutations, BRAF mutations render it continually active and usually involves the 
point mutation that results in substitution of thymidine to adenine at nucleotide 
1799, resulting in substitution of valine to glutamic acid (V600E mutation) (9, 
17).  
 
1.3.2.2  Lynch syndrome/HNPCC 
Dr Alfred Warthin described the first case of hereditary CRC, over a hundred 
years ago, which he designated family G.  In 1971, Lynch and Krush 
subsequently updated studies on family G with what came to be known as Lynch 
syndrome (HNPCC).  It is an autosomal dominant condition caused by germline 
mutations in MMR genes.  These include MLH1 (3p21), MSH2 (2p21-22), MSH6 
(2p16) and PMS2 (7p22).  A recent germline mutation in the TACSTD1 gene 
which encodes the epithelial cell adhesion molecule (Ep-CAM) has also been 
identified (6, 18).  It is located upstream of MSH2 on chromosome 2 and is a rare 
mutation accounting for 1-3% of cases which results in epigenetic silencing of 
MSH2.  
 
Patients with HNPCC usually develop multiple tumours between 20-30 years of 
age in the colon and are at higher risk of developing extra colonic tumours 
including endometrial, ovarian, pancreatic, small bowel, hepatobiliary, skin, brain 
and urethral tumours (18).  The lifetime risk of developing CRC in HNPCC is 
approximately 85% (6). 
 
Guidelines have been developed to identify patients at risk of HNPCC.  It is 
recommended that MSI testing be performed on all patients fulfilling the criteria 
with referral to a geneticist.  Examples of the guidelines include the Revised 
Bethesda criteria summarized below (12, 18). 
Revised Bethesda Guidelines 
1. CRC diagnosed in patients <50 years 
2. Presence of synchronous, metachronous colorectal, or other HNPCC 
associated tumour regardless of age 
3. MSI-H histology in a patient <60 years of age 
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4. CRC diagnosed in ≥ 1 first degree relative with an HNPCC related 
tumour, with one of the cancers diagnosed <50 years 
5. CRC diagnosed in ≥ 2 first or second degree relatives with HNPCC 
related tumour regardless of age 
A large family of approximately 500 individuals, who are at increased risk for 
HNPCC syndrome on account of a transversion mutation in MLH1 has been 
identified in the remote rural village of Kleinsee in the Northern Cape province of 
South Africa, 500km from Cape Town.  This family demonstrates anatomic site 
specific HNPCC, in that increased risk for malignancy in family members is 
largely restricted to the colon (19).  
 
1.3.3 CpG island methylator phenotype (CIMP) pathway 
This is one of the newer pathways that was originally grouped with MSI and 
involves epigenetic alterations (methylation or histone modification) that affect 
gene expression.  DNA methylation commonly occurs at the 5’-CG-3’ (CpG), 
usually in promoter regions resulting in gene silencing providing another 
mechanism of inactivation of TSGs.  Increased methylation is seen with 
increasing age, smoking, injury and chronic inflammation (8, 20). 
 
The CpG islands are regions in the genome rich in cytosine-phosphate-guanine 
(CpG) dinucleotides where cytosine DNA methylation does not covalently 
modify.  CIMP positivity is found in 35-40% of CRCs and has been identified in 
adenomas.  Genes silenced by hypermethylation include APC, MLH1, MCC, 
MGMT, p16, p14 and several others, resulting in repression of these important 
tumour suppressor genes (8, 9, 20). 
 
CIMP characterisation is based on analysis of various genes but the consensus for 
the exact panel of CpG sites for CIMP analysis has not been reached.  A review 
by Curtin et al demonstrated 8 different studies using different CIMP panel 
markers and in all 8 BRAF V600 mutation had been observed (21). 
 
The “traditional”/classic panel to assess CIMP included: MLH1, CDKN2a (p16), 
methylated in tumours (MINTS) 1, 2 and 31.  The cases were divided as follows 
on assessment of CIMP status in serrated polyps in the study (22): 
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No loci positive:  CIMP negative 
One locus positive:  CIMP low 
Two or more loci positive: CIMP positive  
 
CIMP status has been implicated in two pathways in sporadic tumours: CIMP 
high (CIMP-H) related to BRAF mutations and CIMP low (CIMP-L) related to 
KRAS mutations.  Tumours characterized as CIMP positive based on the classic 
panel include both CIMP-H and CIMP-L. 
  
In the study by Weisenberger et al the “new” CIMP panel included: CACNA1G, 
IGF2, NEUROG1, RUNX3 and SOCS1, based on the stepwise screen of 195 
markers.  CIMP positive was defined by methylation of at least three markers (8). 
 
Finally in two comprehensive DNA methylation studies, several CpG sites (202 
CpG sites and 20 panel markers ) were analysed (21).  The emergence of two 
methylation panels as classifiers were proposed: the first to identify high 
methylated tumours (strongly associated with BRAF) and to distinguish between 
intermediate (associated with KRAS) and low methylation groups.  
 
CIMP-high CRC accounts for 15-20% of sporadic CRCs and has overlapping 
phenotypic features with MSI-H tumours.  It is often poorly differentiated, of 
mucinous or signet ring histology and seen in the proximal colon (8).  In addition, 
these tumours harbour KRAS and/or BRAF mutations as mentioned above (9).  
 
The prognostic significance of CIMP remains ill defined.  CIMP+ tumours confer 
a worse prognosis than MSI-H tumours.  However, if both MSI-H and CIMP 
positivity are present, the prognosis improves compared with MSI-/CIMP+ 
tumours (9).  Jass suggested a classification based on MSI and CIMP status and 
included the following 5 molecular subtypes (23): 
1. CIMP high/MSI high – originates in sessile serrated adenomas (see below) 
together with BRAF mutations and MLH1 methylation. 
2. CIMP high/MSI low – originates in sessile serrated adenomas together 
with BRAF mutations and methylation of multiple genes. 
13 
 
3. CIMP low/MSI low or MSS – Occurs in tubulovillous adenomas or 
traditional serrated adenomas and is characterised by CIN, KRAS mutation 
and MGMT methylation. 
4. CIMP-/MSS – originates in the traditional adenoma and is characterized 
by CIN. 
5. CIMP negative/MSI-H – seen in HNPCC; negative for BRAF mutations. 
 
In summary, serrated polyps are the precursors of types 1 and 2 CRCs while types 
4 and 5 evolve through the adenoma-carcinoma sequence, while type 3 CRCs 
may arise within either type of polyp.  However, it is thought that the traditional 
serrated adenoma does not belong to the serrated neoplastic pathway (see below) 
(24). 
 
1.3.4 Alternative serrated neoplastic pathway 
It is thought that between 20 and 35% of sporadic colorectal carcinomas arise 
from this alternative pathway, developing from a “serrated polyp” and accounts 
for at least 15% of all CRCs (24).  These polyps are composed of epithelial 
infoldings that create a saw-tooth appearance.  The nomenclature continues to be 
controversial in this group.  This pathway is seen in elderly women (average age 
of 61 years), particularly in the right side of the colon.  It is characterised by 
excessive methylation, propensity for BRAF mutations and MSI.  It is associated 
with sessile serrated adenomas/polyps, which are different from hyperplastic 
polyps.  The WHO classifies serrated polyps into three categories: hyperplastic 
polyps, sessile serrated adenomas and traditional serrated adenomas (24, 25). 
 
Hyperplastic polyps, which include goblet cell hyperplastic polyps (GCHPs), 
microvesicular hyperplastic polyps (MVHPs) and mucin poor hyperplastic polyps 
(MPHP) are recognized by histology and classified according to the morphology 
of the lining cells, GCHPs are associated with KRAS mutations while MVHPs are 
linked to BRAF mutations.  The polyps are small, distally located and have little 
or no risk of progression to malignancy (2, 24). 
 
Sessile serrated adenomas (SSAs) are located predominantly in the right colon. 
These polyps differ from hyperplastic polyps, in that the crypts are distorted, 
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branched and dilated resembling an “L” or inverted “T”.  SSAs may have 
cytologic atypia and only rarely display dysplasia.  However, again the 
nomenclature is still controversial being disputed among experts (24). 
  
Traditional serrated adenomas (TSAs) are located in the distal colorectum and are 
rare accounting for 1% of polyps.  Morphologically, there is greater villous or 
tubulovillous pattern with ectopic crypt foci and epithelial cells displaying 
eosinophilic cytoplasm and “pencillate” nuclei.  The ectopic crypt foci, help in 
distinguishing TSAs from SSAs.  Foci resembling conventional tubulovillous 
adenomas have been described, the exact significance is uncertain.  Although this 
polyp shares its name with SSA, it is not felt to belong to part of this pathway. 
These lesions are different morphologically and pathogenetically (24).  
 
Two molecular pathways have been proposed (9, 24): 
1. BRAF-mut with CIMP-H and MSI or MSS cancers.  There is usually promoter 
methylation of MLH1 in the MSI CRCs.  This is seen in the SSA pathway. 
MVHPs are thought to be precursors of SSAs (24). 
2. KRAS-mut with CIMP-L and MSS are seen in TSAs which are thought not to 
belong to the serrated neoplastic pathway by some authors.  BRAF may also be 
mutated.  GCHPs are thought to be precursors of TSAs (24).  
 
Overall, the detection and pathological identification are not yet optimised. 
Pathologists are confused over the exact nomenclature due to the different fields 
of thought, and need to be aware of this minor yet significant contribution the 
serrated neoplastic pathway has in CRCs.  This will allow for greater recognition 
of these polyps and help standardise reporting. 
 
1.3.5 MicroRNAs 
MicroRNAs (miRNA) are short non-coding RNA sequences that bind to mRNA 
and control translation of complementary genes.  MiRNA dysregulation is 
suggested to play a role in carcinogenesis when miRNA targets TSGs or 
oncogenes through silencing or overexpression respectively.  MiRNAs that allow 
tumour growth may be upregulated through transcriptional activation and/or 
amplification of the miRNA encoding gene.  Those that are decreased and 
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potentially unfavourable to growth are silenced by deletion or epigenetic 
modifications.  There appears to be a role for miRNAs in CRC initiation, 
progression and development.  In addition, miRNAs are much more stable 
molecules than DNA or RNA, due to their small size allowing detection in blood, 
and formalin fixed tissue (26, 27).  
 
Some of the miRNA findings in CRC carcinogenesis include [23,24]: 
- miRNA-143 and miRNA-145 are reduced indicating tumour suppressive 
activity. 
- miRNA-21 is elevated and has important roles in initiation, progression and 
metastasis.  Elevated levels of miRNA-21 are found in adenomas. 
- miRNA-135a and miRNA-135b downregulate the APC gene in the Wnt 
pathway. 
- miRNA-92 and miRNA-17 were elevated in preoperative samples of plasma 
from CRC patients and decreased following removal of the cancers.   
 
In the future, miRNAs may be potential molecular classifiers, early detection 
biomarkers and therapeutic targets for CRC. 
 
1.3.6 Epigenetic changes 
These changes, seen in approximately 40% of CRCs, alter genetic expression, 
without changes to the DNA nucleotide sequences and are conveyed during 
cellular division.  The DNA helix is wrapped around histone proteins into 
chromatin that is regulated by epigenetic factors, involving methylation, histone 
modification and non-coding RNAs.  It influences expression of genes by 
inducing modifications in the chromatin at gene promoter areas, affecting the 
accessibility of transcription factors (28). 
 
The genetic code provides the blueprint for cellular protein, while the epigenetic 
code controls elaboration of the blueprint (9, 20).  The two examples that will be 
discussed are histone modification and DNA methylation. 
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1.3.6.1 Histone modification 
Histones are highly alkaline proteins that are responsible for packaging DNA into 
nucleosomes, which are the basic units of chromatin.  It consists of a 146-bp loop 
of DNA wrapped over an octamer of core histones (H2A/H2B dimers and H3/H4 
tetramer).  Modifications of histones include acetylation, methylation, 
phosphorylation and ubiquitinylation, which are reversible and can change 
inactive heterochromatin to active euchromatin, and vice versa.  The 
modifications occur at the N-terminal or C-terminal domains of the histones.  The 
enzymes involved in the modifications include histone acetyltransferases (HATs), 
histone deacetylases (HDACs) and histone methyltransferases.  It is the balance 
of these enzymes and related proteins that allow for normal functioning of cells 
(20). 
 
The modifications that have been identified in aberrant TSGs in CRC include 
deacetylation and methylation of lysine 9 residue of core histone H3.  Acetylation 
results in gene expression whereas methylation is associated with gene silencing. 
These modifications are mutually exclusive.  A pattern of change in core histone 
H4 (monoacetylation from lysine 16 and trimethylation from lysine 20) has also 
been proposed as a universal marker for malignant transformation in CRCs.  
Histones may also be replaced with variants e.g. H3.3 for the canonical H3 and 
H2A.Z variant for H2A (20).  
 
1.3.6.2  DNA methylation 
The enzymatic modification of cytosine bases in DNA to form 5-methylcytosine 
is the most widely investigated and understood mechanism of epigenetic 
modification. 
 
In the human genome, methylation of cytosine residues commonly occurs at the 
CpG islands but can occur at 5’-CA-3’ or 5’-CT-3’ residues.  Approximately 70% 
of all CpG dinucleotides in the human genome are heavily methylated, and the 
remaining CpG rich regions are present in promoters and first exons of genes. 
Hypermethylation of CpG islands have been discussed in the CIMP pathway.   
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In addition to hypermethylation, global DNA hypomethylation can also occur, 
first noted in the 1970s, and found in lesions across the spectrum from 
hyperplastic polyps, adenomatous polyps to carcinomas.  Highly repeated DNA 
sequences include short interspersed transposable elements (SINEs) and long 
interspersed transposable elements (LINEs) which are seen in approximately 40% 
of human DNA and are normally methylated but become hypomethylated in 
CRC.  The epigenetic change increases chromosome breakage, disrupting gene 
function or activating oncogenes (20).  
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1.4 Hereditary colorectal cancer syndromes 
Table 1: Genetics of inherited colorectal tumour syndromes (adapted from 
reference 5) 
Syndrome Features Gene(s)  
FAP Multiple adenomatous polyps (>100) and 
carcinomas of the colon and rectum 
APC 
Gardner Same as FAP with desmoids tumours and 
mandibular osteomas 
APC 
Turcot Adenomatous polyposis, colorectal cancer and 
brain tumours, usually glioblastomas    
APC, MLH1, 
PMS2 
Attenuated 
FAP 
 Less than 100 adenomatous polyps APC 
(5’mutations) 
HNPCC High risk of colorectal cancer without 
extensive polyposis. Increased risk of 
extraintestinal malignancies. 
MSH2, 
MLH1, 
PMS2, 
MSH6, GTBP 
Peutz-Jeghers Hamartomatous polyps throughout the GIT 
with mucocutaneous pigmentation. Risk of GI 
and non-GI cancers are increased. 
LKB1  
(STK11) 
Cowden  Multiple hamartomatous polyps involving the 
GIT. Increased risk of breast, thyroid and 
uterine cancers. Risk of GI cancer unclear 
PTEN 
Juvenile 
polyposis 
syndrome 
Multiple hamartomatous / juvenile polyps.  
Variable risk in colon and stomach cancers 
DPC, 
BMPR1a 
PTEN 
MAP Multiple adenomatous GI polyps, often with 
KRAS mutations 
MYH 
 
The hereditary syndromes arising from germline mutations account for less than 
5% of colorectal carcinomas (8) (Table 1).  Familial adenomatous polyposis and 
Lynch syndrome account for the majority of syndrome associated colorectal 
cancer. 
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1.4.1 Familial Adenomatous Polyposis (FAP) 
Familial adenomatous polyposis is an autosomal dominant disorder which affects 
1 in 12 000 individuals and accounts for 0.5-1% of all CRCs (5, 8).  It involves a 
germline mutation in the APC gene, a component of the Wnt pathway.  The 
lifetime incidence of CRC is 100% and the mean age of diagnosis is 36 years. 
Hence, prophylactic removal of the colon early in the patient’s life is the 
treatment of choice.  An attenuated form of FAP exists, that is less aggressive and 
characterised by fewer polyps and later onset of disease (5).  
 
Most of the APC mutations associated with FAP are frameshift or nonsense 
mutations that lead to a premature truncated protein.  Frameshift mutations are 
more common than nonsense mutations (3:1 ratio).  In addition, the distribution of 
the mutations is different in the attenuated variant of FAP.  Mutations in codons 
1250 and 1464 are associated with profuse polyposis in contrast to mutations that 
involve the N-terminal of codon 157 or near the C-terminus which lead to 
attenuated polyposis.  Two hotspots, codons 1061 and 1309, account for 35% of 
mutations identified in FAP (5).  
 
Extracolonic manifestations include, osteomas, dental anomalies, cutaneous 
manifestations, hypertrophy of the retinal pigment epithelium, desmoids tumours 
and extracolonic carcinomas.  Colonic polyposis together with brain tumours 
(glioblastomas) occur in Turcot syndrome.  Polyposis together with epidermoid 
cysts, desmoid tumours and osteomas are seen in Gardner syndrome (8).  
 
1.4.2 Lynch syndrome (Hereditary non-polyposis colorectal cancer) 
This syndrome Is discussed under the MSI pathway. 
 
1.4.3 MYH-associated polyposis (MAP) 
This is an autosomal recessive disorder resulting from biallelic mutations in the 
MYH gene, located on chromosome 1p35.  It is a base excision repair gene 
following oxidative damage to DNA, thereby leading to increased GC-to-AT base 
pair transversion mutations when defective. 
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The patients with MAP generally have between 10 to 100 colonic polyps, with 
CRC developing in approximately 65% of patients, but at a later age (mean age 
45 years) than FAP.  Gastric and small intestinal polyps can occur but other 
extraintestinal manifestations are less common than FAP (8). 
 
1.4.4 Hamartomatous polyposis syndromes 
1.4.4.1 Peutz–Jeghers syndrome 
This is an autosomal dominant syndrome characterized by hamartomatous polyps 
throughout the gastrointestinal tract as well as mucocutaneous melanin 
deposition.  There is also an increased risk of adenomatous polyps with a 
predisposition to gastric, intestinal and extra-intestinal cancers.  There is a 
germline mutation in the STK11/LKB1 tumour suppressor gene, which leads to 
increased activation of the mammalian target of rapamycin (mTOR) pathway, a 
major regulator of cell growth (8). 
 
1.4.4.2 Juvenile polyposis syndrome 
This autosomal dominant syndrome is associated with numerous juvenile polyps 
throughout the GIT and is ten times less common than FAP.  These patients are at 
increased risk of developing GIT and pancreatic cancers.  In 50-60% of patients 
Smad4 or BMPR1A mutations are identified (5, 8).  
 
1.4.4.3 Cowden syndrome 
This syndrome sometimes referred to as PTEN hamartoma syndrome involves 
hamartomas consisting of derivatives of all three germ layers.  Hamartomatous 
polyps can occur throughout the GIT.  In addition, these patients are at increased 
risk of extraintestinal malignancies, including breast, thyroid and endometrial 
carcinoma (8). 
 
1.5 Regulation of the cell cycle 
Dividing eukaryote cells pass through a series of stages known collectively as the 
cell cycle: two gap phases (G1 and G2); an S (synthesis) phase, where the genetic 
material is duplicated; and the M phase in which mitosis occurs.  In order to 
undergo replication cells have to move from the G0 or “resting phase” of the cell 
cycle to the G1 phase.  The progression through the various phases of the cell 
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cycle are driven by cyclins, cyclin dependent kinases (CDK) and their inhibitors 
(e.g. p21 and p27) (29, 30).  
 
1.5.1 Cyclins D1 and E 
G1 phase cyclins include cyclin D and E, activation of which results in the 
proliferation of cells.  Cyclin D1 appears in the mid G1 phase and is no longer 
detectable in the S phase.  It acts together with CDK4 and 6, that form active 
complexes that promote G1 to S phase progression through the inactivation of 
retinoblastoma protein (pRb) via phosphorylation.  In the G1 phase of the cell 
cycle, cyclin D1-CDK4 complex releases active E2F by phosphorylating pRb, 
which in its hypophosphorylated form is bound to E2F.  Free active E2F in turn 
activates the transcription of genes important in S phase progression (30).  
Usually following the mutation of the APC gene, cyclin D1 is activated via the 
Wnt-β-catenin pathway discussed earlier.  In addition, recent studies have shown 
that cyclin D1 regulates other transcription factors (31).  It is an unstable 
molecule and is degraded through the ubiquitin-proteasome pathway.  
 
Cyclin E associates with CDK2, resulting in diminished requirement for growth 
factors, accelerating the G1 phase, which suggests that cyclin E is responsible for 
G1 phase progression.  Cyclin E/CDK2 complexes phosphorylate pRb and thus 
release more active E2F, which in turn stimulates, amongst others, its own 
transcription (5). 
 
Usually pRb requires phosphorylation of cyclin D1/CDK4 prior to the action of 
cyclin E/CDK2.  However, some studies demonstrated that malignant cells use 
one cyclin molecule to phosphorylate pRb preferentially over the other, making 
the other cyclin redundant (29). 
 
High copy amplification of the cyclin E gene is found in only 5% of CRCs.  This 
is due to inactivation of the FBXW7 gene, which encodes an F-box protein.  This 
protein forms part of the SCF ubiquitin ligase complex and may also regulate 
other oncogenic factors like c-myc, c-jun and Notch proteins.  It is inactivated in 
approximately 20% of CRCs (5). 
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1.5.2 Cell cycle inhibitors – p21, p27 and p53 
The two main classes of CDK inhibitors are the Cip/Kip and the INK4/ARF 
families.  There are three main components of the Cip/Kip family: p21, p27 and 
p57 that inactivate the complexes between cyclins and CDKs (30).  
 
p27 responds to antimitogenic signals like the growth suppressor, transforming 
growth factor β (TGFβ).  It regulates G0 to S phase in the cell cycle and inhibits 
cyclin E/CDK2 and regulates function of cyclin D1/CDK4 and cyclin D1/CDK6.  
Regulation of p27 is achieved by the ubiquitin mediated protein degradation.  
Interestingly, the F-box protein (mentioned above), SKP2 has been identified as 
the substrate recognition component that targets p27 for degradation (32).  Studies 
in CRCs show mixed results regarding prognosis, with 9 out of 13 retrospective 
multivariate analyses demonstrating a 1.43-11 fold increase in disease recurrence 
or death with reduced expression of p27 (32). 
 
p21 is under the control of p53, a tumour suppressor that is mutated in a large 
proportion of human cancers.  p21 has a pro-apoptotic as well as an anti-apoptotic 
role and may also facilitate invasion and metastasis, through p21-activated kinase 
1 (PAK-1). Cellular senescence and aging of stem cells have also been linked to 
p21.  Most studies show no prognostic value of p21 in CRC (33).  
 
p53 functions as a transcriptional regulator of genes that encode proteins which 
function as cell cycle check points.  It promotes apoptosis, cell cycle arrest and 
antiangiogenic pathways in cells with wild type p53 function, secondary to DNA 
stresses like strand breakage, telomere erosion and hypoxia.  It is negatively 
regulated by MDM2, E3 ubiquitin ligase and MDM4 which promote 
ubiquitination (5).  
 
p53 is the target of 17p LOH (as discussed above) and is seen in 70% of CRCs 
with the remaining p53 allele demonstrating a somatic mutation.  The mutations 
include missense defects, often occurring at codons 175, 245, 248, 273 and 282.  
Only a few sporadic CRCs and most adenomas lack 17p LOH, implying that 
LOH is closely associated with adenoma-carcinoma transition (5). 
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1.6 c-myc 
The c-myc proto-oncogene encodes a transcription factor that regulates genes 
involved with cell cycle progression, cell adhesion, survival and cellular 
metabolism.  It is expressed in numerous human malignancies.  High copy 
amplification of the c-myc gene is seen in 5-10% of CRCs while moderate 
increases are seen in approximately 30% of CRCs. 
 
Activation of the c-myc gene expression is central to signal transduction via the 
APC tumour suppressor protein which negatively regulates β-catenin.  β-catenin 
is able to directly activate c-myc expression, so that when APC is inactivated, 
activation of β-catenin results (5). 
 
1.7 Matrix Metalloproteinase 7 (MMP-7) 
The MMP family of zinc-dependent proteinases are composed of 23 members, 
and based on their structure are divided into secreted-type MMP and membrane-
anchored MMP.  MMPs are thought to be responsible for pathological tissue 
destruction due to the ability to catabolize ECM components.  However, they are 
also able to break down growth factors, cytokines and their receptors.  Tissue 
inhibitors of metalloproteinases (TIMP) of which there are various subtypes, are 
the major physiological inhibitors of MMPs (34).  The MMPs are overexpressed 
in human cancers and are associated with an aggressive malignant phenotype and 
adverse prognosis (35). 
 
MMP-7 (Matrilysin, pump-1) is the smallest known member of the MMP family 
and its protein product was first identified in the culture medium of a human 
rectal carcinoma cell line.  MMP-7 degrades various ECM proteins including 
proteoglycans, fibronectin, entactin, laminin, gelatin, type IV collagen, type X 
collagen and elastin (34, 36).  It therefore supports tumourigenesis and 
progression.  It also has the capability of degrading MMP-2 and MMP-9.  It is 
elevated in numerous primary cancers including breast, ovary, endometrial, lung, 
stomach carcinomas and oesophageal squamous cell carcinomas.  In addition, 
MMP-7 is a target gene of the Wnt signalling pathway described above. 
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MMP-7 is overexpressed both in dysplasia and CRCs and MMP-7 mRNA 
expression correlated with the stage of CRC progression in a study by Polistena et 
al (36).  In CRC hepatic metastases, a study has shown variable degrees of MMP-
7 overexpression in the metastatic carcinoma when compared to normal liver 
tissue (37).  In addition, studies have shown an increased expression of MMP-7, 
following neoadjuvant radiotherapy for rectal cancer, suggesting a role for tissue 
remodelling after injury (36). 
 
1.8 Clinical features and special investigations 
Usually patients experience a change in bowel habits, constipation being 
common, because of the obstructive effect of the mass, especially in the left 
colon.  Tumours are also prone to ulceration, and haematochezia and anaemia can 
be presenting features.  Abdominal distension, bowel obstruction and perforation 
can be late presentations of the tumour, sometimes encountered as a surgical 
emergency.  Tenesmus and rectal bleeding are symptoms seen in lesions in the 
rectosigmoid area.  Non-specific symptoms include abdominal pain, fever and 
weight loss (2). 
 
Imaging studies allow for detection and staging of the tumour.  Computer assisted 
tomography (CT) has largely replaced barium enemas in first world settings.  
Magnetic resonance imaging (MRI), cross sectional imaging by CT and 
transrectal ultrasound can also estimate depth of invasion and metastases.  
Colonoscopy allows observation of the entire mucosal surface, identifying the 
lesion and other benign polyps.  Biopsy or therapeutic removal of superficial 
adenomas and carcinomas can also achieved by snare polypectomy, mucosal 
resection or submucosal dissection (2).   
 
1.9 Pathology 
1.9.1 Macroscopic pathology 
The majority (65%) of the carcinomas occur in the rectosigmoid region of the 
large bowel followed by the ascending colon (2).  The molecular pathology 
described above also has site differences.  Tumours with high levels of 
microsatellite instability (MSI-H) and CIMP-H are frequently located in the 
caecum, ascending colon and transverse colon (2, 9).  
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 The majority of tumours are ulcerating producing a degree of stenosis and 
obstruction.  The carcinomas can be exophytic/fungating with predominantly 
intraluminal growth or annular with circumferential involvement of the wall 
resulting in stenosis and dilatation.  The diffusely infiltrative/linitis plastica 
pattern is extremely rare.  The carcinomas in the ascending and transverse colons 
tend to be exophytic and those in the descending colon, annular and constricting 
(2).  
 
1.9.2 Microscopic pathology 
The typing of CRCs is based on the predominant histomorphology of the tumour.  
The subtypes according to the WHO classification include (2): 
- Adenocarcinoma, NOS 
- Adenocarcinoma special types: 
Cribriform comedo type adenocarcinoma, medullary carcinoma, 
micropapillary carcinoma, mucinous adenocarcinoma, serrated 
adenocarcinoma and signet ring cell adenocarcinoma. 
- Adenosquamous carcinoma 
- Spindle cell carcinoma 
- Squamous carcinoma 
- Undifferentiated carcinoma 
 
The vast majority of the carcinomas are adenocarcinomas and its variants (>90%).  
These carcinomas are positive with cytokeratin 20, negative with cytokeratin 7 
and express the transcription factor CDX2. 
 
The tumour is designated mucinous when more than 50% of the lesion is 
composed of pools of extracellular mucin (2, 38).  If the mucinous component 
forms less than 50% of the tumour it is categorized as having a mucinous 
component.  The epithelial component can include acinar structures, layers of 
tumour cells, single tumour cells or signet ring cells.  Most mucinous 
adenocarcinomas are MSI-H and low grade.  The mucinous carcinomas that are 
MSS or MSI-L behave as high grade lesions (2). 
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The signet ring variant of CRC is defined by the presence of >50% signet ring 
cells.  Similar to the mucinous tumours, those that are MSI-H are low grade while 
those that are MSS and MSI-L behave aggressively (2). 
 
The medullary variant is rare and displays a sheet-like growth of malignant cells, 
with a prominent intraepithelial lymphocytic infiltrate (2, 38).  The cells have 
vesicular nuclei with prominent nucleoli.  This variant is almost exclusively seen 
in MSI-H tumours with a favourable prognosis. 
 
The serrated variant has architecture similar to a serrated polyp and may have 
mucinous, cribriform and trabecular areas.  The molecular alterations associated 
with this histological type include MSI-L, MSI-H, BRAF mutations and CpG 
island methylation.  The cells have clear to eosinophilic cytoplasm, with vesicular 
nuclei with limited or absent tumour necrosis (<10% necrosis) (39). 
 
The cribriform comedo-type adenocarcinomas have large cribriform glands with 
central necrosis similar to that seen in the breast.  These tumours are usually MSS 
with CpG island hypermethylation (2). 
 
The micropapillary adenocarcinomas have clusters of tumour cells with stromal 
spaces that mimic vessels (pseudovascular).  These malignant cells are usually 
positive for MUC1 on immunohistochemistry (2). 
 
The adenosquamous carcinoma has both adenocarcinoma and squamous cell 
carcinoma components.  A pure squamous cell carcinoma is extremely rare.  
Spindle cell carcinoma is usually a biphasic tumour with a spindle 
cell/sarcomatoid component that shows patchy immunoreactivity with 
cytokeratins.  Undifferentiated carcinomas lacking morphological, 
immunohistochemical and molecular evidence of differentiation beyond that of an 
epithelial tumour are also rare. 
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1.10 Aims and Objectives 
 
Aim:  To determine the comparative histopathology and immunohistochemical 
expression of cell cycle regulators and MMR proteins in different cohorts of CRC 
patients. 
 
The specific objectives of the study were: 
• To characterise the macroscopic and microscopic pathology in three 
cohorts of patients’. The cohorts include patients’ with CRCs that are < 50 
years and mutation negative,   < 50 years and mutation positive and more 
than 50 years (sporadic).  
• To investigate the immunoexpression of the cell cycle regulators (p21, 
p27, p53, c-myc, cyclin D1 and cyclin E) and MMP-7 in each cohort 
• To compare the immunoexpression of each marker between cohorts. 
• To correlate the immunoexpression of each marker with tumour type, 
stage and grade.  
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CHAPTER 2 
 
2. MATERIALS AND METHODS 
2.1 Ethics approval 
Ethics approval was obtained from the University of Cape Town (UCT) Faculty 
of Health Sciences Human Research Ethics Committee (Reference number 
050/2007).  The research proposal was approved by the Department of Clinical 
Laboratory Sciences Research Committee and the Faculty of Health Sciences 
Postgraduate Committee at UCT.  Funding for this study was obtained from the 
National Health Laboratory Service Research Trust. 
 
2.2 Sample selection 
An electronic search of the laboratory information system database of the 
Division of Anatomical Pathology, National Health Laboratory Service–Groote 
Schuur hospital was performed.  The search included resection specimens of 
colorectal carcinoma occurring in patients older than 50 years between January 
1996 and December 2013.  In addition, mutation positive and mutation negative 
resection cases, confirmed by the Division of Human Genetics were also 
provided. The following mutations were tested:   
MSH2 EXON8 c.1340_1341insGG, 
MSH2 EXON7 c.1221_1222delCT, 
MSH2 EXON3 c.387_388delTC, 
MSH2 EXON15 c.2502_2508delTAATTTC and 
MLH1 Exon13 c.1528C>T. 
 
Archived stained slides of the cases were reviewed.  The diagnosis in each case 
was confirmed and the morphological data recorded (including lymph node 
status) and further information from the reports, also recorded.  During review of 
the haematoxylin and eosin (H&E) sections a suitable block of tumour tissue was 
selected for immunohistochemical staining.  The block containing predominant 
tumour, and minimal haemorrhage and necrosis was selected.  In most cases 
adjacent morphologically normal mucosa was present.  Tissue blocks were 
retrieved from the archives of Division of Anatomical Pathology and 4μm 
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sections were cut for immunohistochemistry.  The cases were allocated random 
case numbers after retrieval of reports and patient names were not used. 
 
A retrospective, comparative study between three different patient cohorts was 
undertaken.  The three patient cohorts included: 
Cohort 1: Patients younger than 50 years of age without known mismatch repair 
gene mutations (n=17). 
Cohort 2: Patients younger than 50 years of age with confirmed mismatch repair 
gene mutations (n=15). 
Cohort 3: Patients older than 50 years of age with sporadic colorectal carcinoma 
(n=28). 
 
2.3 Antibodies 
 
Table 2: Primary antibodies 
Primary antibody 
(Mouse/Rabbit) 
(mono/poly) 
Clone Supplier Antigen 
Retrieval 
Dilution Incubation 
time  
Positive 
control 
p21 (M)(m) Waf1 Novocastra EDTA pH8 1:30 1 hour tonsil 
p27 (M)(m) 1B4 Novocastra EDTA pH8 1:20 1 hour  tonsil 
p53 (M)(m) DO-7 Dako EDTA pH8 1:100 1 hour tonsil 
Cyclin D1 (R)(m) SP4 Abcam EDTA pH8 1:400 1 hour Mantle cell 
lymphoma 
Cyclin E (M)(m) 13A3 Dako EDTA pH8 1:60 1 hour Placenta 
c-myc (M)(m) 9E11 Novocastra EDTA pH8 1:200 1 hour Tonsil 
MMP7 (M)(m) ID2 Abcam Tris EDTA 1:50 1 hour Colon 
MLH1 (M)(m) M1 Ventana EDTA pH8 prediluted 20 min Colon 
MSH2 (M)(m) FE11 Calbiochem EDTA pH8 1:250 1 hour Colon 
MSH6 (M)(m) 44/M
SH6 
BD 
Bioscience 
EDTA pH8 1:500 1 hour Colon 
(Key: M – mouse, R-rabbit, m – monoclonal and p - polyclonal) 
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A negative reagent control, in which the primary antibody was replaced by PBS 
(buffer), was run simultaneously for each antibody (Table 2). 
 
PMS2 was not included in the immunohistochemical analysis of MMR proteins 
since MLH1 forms heterodimers with PMS2 and MLH1 mutations are more 
common.  Another important factor was the limited funding and the need to work 
within a tight budget. 
 
2.4 Immunohistochemistry Method 
 
Table 3: Kits used for the IHC protocol 
KITS SUPPLIER 
Envision HRP System Labelled Polymer Anti-mouse Dako - CA, USA 
Envision HRP System Labelled Polymer Anti-rabbit Dako - CA, USA 
Liquid DAB + Substrate chromogen system Dako - CA, USA 
 
• Four micron tissue sections were cut from paraffin wax embedded tissue 
blocks, picked up onto Histobond slides (Marienfeld-Germany) and heat fixed 
on a hotplate for 10-15 minutes. 
• Sections were dewaxed through xylene, cleared in ethanol and rehydrated in 
water. 
• Endogenous peroxidase activity was blocked by treating the slides with a 3% 
hydrogen peroxide (H2O2) solution for 10 minutes. 
• Slides were washed well in water. 
• Antigen retrieval was performed by pressure-cooking slides in either Tris-
EDTA (pH9) (MMP7 only) or EDTA (pH8) (p21, p27, p53, cyclin D and E, 
c-myc, MLH1, MSH2 and MSH6) for 1 minute 30 seconds at full pressure. 
• The sections were allowed to cool for 10 minutes. 
• This was followed by washing in tap water. 
• Thereafter, slides were rinsed with phosphate buffered saline solution (PBS 
pH 7.6) (Oxoid-Hampshire, England). 
• Non-specific binding was blocked by treating slides with a 5% goat serum 
solution (DAKO- Denmark). 
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• Serum was then drained off and sections were incubated with primary 
antibody at room temperature at specified times and dilutions (Table 2). 
• The slides were then washed well with PBS buffer. 
• This was followed by incubation with DAKO Envision labelled Polymer, 
HRP (DAKO- USA) for 30 minutes at room temperature (Table 3). 
• Sections were washed well with PBS buffer. 
• Positivity was developed by applying the chromogenic substrate 3.3 
diaminobenzidine (DAB) (DAKO- USA) for 5-10 minutes. 
• Slides were washed in running tap water and counterstained with Mayers 
haematoxylin for approximately 3 minutes. 
• After washing in running tap water, sections were blued in ammoniated water. 
Finally, the slides were then dehydrated through alcohols, cleared with xylene 
and mounted with Entellan (MERCK- Germany) and cover-slipped. 
 
2.5  Microscopic assessment of immunohistochemical stains 
The proportion of positive cells as well as the intensity of staining was recorded 
for each stain and for each case.  The location of staining, nuclear and/or 
cytoplasmic was recorded. 
 
Proportion score  Proportion of cells staining 
0 Staining in <5% of tumour cells 
1+ Staining in 6-25% of tumour cells 
2+ Staining in 26-50% of tumour cells 
3+ Staining in 51-75% of tumour cells 
4+ Staining in >75% of tumour cells 
 
Intensity score Intensity of staining  
0 No staining 
1+ Weak staining 
2+ Intermediate (moderate) staining 
3+ Strong staining 
32 
 
After determining the intensity and percentage of cells staining, the H-score (HS) 
was calculated, using the multiplication of the two scores, similar to that used in 
breast carcinomas (HS = Intensity of stain x Proportion of cells staining) (40). 
However, for the MSI markers, i.e. MLH1, MSH2 and MSH6, the tumours were 
either designated positive or negative.  According to the College of American 
Pathologists guidelines, weak and patchy nuclear staining in the tumour was also 
designated positive.  Expression of loss, was only made if the internal control 
nuclei (stromal cells, inflammatory cells and epithelial cells) were positive, else 
the case was designated indeterminate/non assessable (38). 
 
2.6 Clinical data and pathological features 
The clinical data recorded were age and gender. 
 
2.6.1  Macroscopic Features 
• Anatomic site of the tumour: rectum, left colon (distal to the splenic flexure 
and proximal to the rectum) or right colon. 
• The greatest dimension of the tumour, shape/configuration 
(annular/constricting, exophytic, mucinous) were recorded from the 
pathology reports. 
• The tumours were staged as per the TNM staging system. 
• Presence of colonic polyps was documented, including type, anatomical 
location and number. 
• Synchronous tumours are defined as two or more primary tumours in the 
excision specimen. 
 
 
2.6.2  Microscopic Features and Study Definitions 
The following variables were assessed: 
• Tumour grade (low or high) 
• Special variant of adenocarcinoma if present as per the 2007 WHO 
classification  
• Mucinous differentiation was also noted and defined as any tumour that had a 
mucinous component between 5% and 100%. 
33 
 
• Tumour infiltrating lymphocytes (TILs) were defined as a lymphoid infiltrate 
where more than 30 lymphocytes were present in 10 HPFs.  The exact nature 
of the lymphocytes (B-cell vs T-cell) was not determined, although it is noted 
in studies that TILs are usually cytotoxic T lymphocytes (41, 42). 
• Crohn’s reaction was defined as a lymphoid reaction with lymphoid follicles, 
with and without germinal centres. 
• Tumour margins as defined by Jass (43). An infiltrative margin does not allow 
a clear demarcation of the tumour invasive front.  On low power examination, 
there is dissection of malignant glands through structures of the bowel wall.  
In contrast, an expanding/pushing border is seen when there is clear 
demarcation of the tumour invasive front. The malignant glands form a 
“round” circumscribed front. 
 
The tumours were classified according to the 2007 WHO classification (2). 
Adenocarcinoma, NOS 
Special variants:  
Cribriform-comedo type,  
Medullary carcinoma,  
Micropapillary carcinoma,  
Mucinous adenocarcinoma,  
Serrated adenocarcinoma and  
Signet ring cell adenocarcinoma. 
Adenosquamous carcinoma 
Spindle cell carcinoma 
Squamous carcinoma 
Undifferentiated carcinoma 
 
2.6.3 Grading of tumours 
In the past, CRCs were graded as well-, moderately, poorly and undifferentiated 
based on the percentage of gland formation and cytomorphology.  However, 
adenocarcinomas are now better classified as “low grade” and “high grade”, due 
to the similar behaviour of well- and moderately differentiated tumours (2, 38).  
In addition, a two-tiered grading system allows for greater reproducibility. 
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Low grade  - Greater than or equal to 50% gland formation. 
High grade - Less than 50% gland formation. 
 
The grading system only applies to “Adenocarcinoma, NOS” (2).  The other 
variants carry their own prognostic significance and grading does not apply (2).  
In addition, when the tumour is heterogeneous, the grading is based on the least 
differentiated component.  
 
2.6.4 Staging of tumours 
CRCs in this study were staged according to the 2009 7th edition TNM tumour 
staging system, which characterises the extent of the lesion according to the 
parameters of depth of invasion of the primary tumour (T), regional lymph node 
involvement (N) and distant metastatic spread (M) (2). 
 
T - Primary tumour 
Tis  Carcinoma in situ: intraepithelial or invasion of lamina propria 
pT1  Tumour invades submucosa 
pT2  Tumour invades muscularis propria 
pT3  Tumour invades subserosa or into non-peritonealised pericolic 
or perirectal tissues. 
pT4  Tumour perforates visceral peritoneum and/or directly invades 
other organs or structures 
T4a  Tumour perforates visceral peritoneum 
T4b  Tumour directly invades other organs or structures 
 
N - Regional lymph nodes 
pN0  No regional lymph node metastasis 
pN1 Metastasis in 1-3 regional lymph nodes 
N1a Metastasis in 1 regional lymph node 
N1b  Metastasis in 2 to 3 regional lymph nodes 
N1c  Tumour deposit(s), i.e. satellites, in the subserosa, or in non-
peritonealised pericolic or perirectal soft tissue without regional 
lymph node metastasis  
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pN2   Metastasis in 4 or more regional lymph nodes 
 
M - Distant metastasis 
M0 No distant metastasis 
M1 Distant metastasis present 
M1a Metastasis confined to one organ 
M1b  Metastasis in more than one organ or peritoneum 
 
Stage Grouping 
Stage T N M 
Stage 0  Tis N0 M0 
Stage I T1, T2 N0 M0 
Stage II T3, T4 N0 M0 
Stage IIA T3 N0 M0 
Stage IIB T4a N0 M0 
Stage IIC T4b N0 M0 
Stage III Any T N1, N2 M0 
Stage IIIA T1, T2 N1 M0 
 T1 N2a M0 
Stage IIIB T3, T4a N1 M0 
 T2, T3 N2a M0 
 T1, T2 N2b M0 
Stage IIIC T4a N2a M0 
 T3, T4a N2b M0 
 T4b N1, N2 M0 
Stage IVA Any T Any N M1a 
Stage IVB Any T Any N M1b 
 
2.7 Statistical analysis 
Statistical analysis was performed using Stata version 13.1 (StataCorpLP, 4905 
Lakeway Drive, College Station, TX 77845, USA).  The distribution of 
continuous data was assessed graphically and using the Shapiro Wilk test.  
Normally distributed data were summarised using means and standard deviations 
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and analysed using parametric methods (independent or paired t-tests as 
appropriate, or analysis of variance for the comparison of 3 or more means).  
Skewed data were summarised using medians and interquartile ranges and 
analysed using non-parametric methods (Mann-Whitney-U-tests or Wilcoxon 
signed rank tests for paired data as appropriate, or the Kruskal Wallis test for the 
comparison of 3 or more medians).  A P-value of < 0.05 was considered 
statistically significant for analyses.  An adjustment for multiple comparisons i.e. 
3 pairs of medians compared, then the P-value for statistical significance was 
0.05÷3=0.017 i.e. P<0.017. 
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CHAPTER 3 
 
3. RESULTS 
3.1 Clinical and Pathological characteristics 
 
Table 4: Characteristics of colorectal carcinomas in the three cohorts 
 
Cohort 1 
(n=17) 
Cohort 2 
(n=15) 
Cohort 3 
(n=28) 
Mean age, years 38.2 42.8 67 
Male , n (%) 9 (53) 8 (53) 15 (54) 
Female, n (%)* 8 (47) 7 (47) 13 (46) 
Synchronous tumours n (%) 1 (6) 3 (20) 0 
Site (includes synchronous tumours), n (%):    
Left  4 (22) 3(17) 15(54) 
Right 8 (45) 14(78) 4(14) 
Rectum 6 (33) 1(5) 9(32) 
Histologic type, n (%)    
Adenocarcinoma, NOS 15 (88) 8 (54) 22 (78) 
Differentiation, n (%):    
Low grade 14 (93) 9 (100) 21 (95) 
High grade 1 (7) 0 1 (5) 
Adenocarcinoma – special types    
Signet ring cell 0 1 (7) 1 (4) 
Medullary 0 1 (7) 1 (4) 
Serrated 0 0 1 (4) 
Mucinous 2 (12) 5 (33) 3 (10) 
Mucinous differentiation, n (%) ** 2 (12) 9 (60) 9 (32) 
Margins, n(%):    
Infiltrating  9 (53) 1 (7) 16 (57) 
Expanding 8 (47) 14 (93) 12 (43) 
Tumour infiltrating lymphocytes, %: 1 (6) 5 (33) 2 (7) 
Crohns-like reaction, %: 5 (29) 8 (53) 12 (43) 
Background Adenomatous Polyps, %: 2 (12) 5 (33) 1 (14) 
pT stage, n(%):    
T1 2 (12) 0 0 
T2 2 (12) 2 (13) 4 (14) 
T3 8 (47) 7 (47) 17 (61) 
T4 5 (29) 6 (40) 7 (25) 
pN stage,n( %):    
N0 7 (41) 7 (47) 14 (50) 
N1 8 (47) 3 (20) 10 (36) 
N2 2 (12) 5 (33) 4 (14) 
Stage, n(%):    
I 2 (12) 1 (7) 4 (14) 
II 5 (29) 6 (40) 10 (36) 
III 9 (53) 8 (53) 13 (46) 
IV 1 (6) 0 1 (4) 
* n = number of cases, ** Mucinous differentiation is defined as any tumour with 5-100% 
mucinous component 
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3.1.1  Cohort 1 – Mutation negative  (n = 17) 
The patients’ ages in this cohort ranged from 25 to 49 years, with a mean age of 
38.2 years.  The gender distribution was near equal, with 8 females and 9 male 
patients.  The tumours were frequently seen in the right colon (45%), followed by 
the rectum (33%) and then the left colon (22%).  The majority of the 
adenocarcinoma, NOS tumours was low grade (93%) and mucinous 
differentiation was seen in 2 (12%) cases only.  A Crohns like reaction was seen 
in 5 (29%) cases with tumour infiltrating lymphocytes seen in 1 case (6%).  Both 
expanding and infiltrating margins were seen with no marked difference (47% 
infiltrating vs 53% circumscribed).  The majority of the cases were stage III 
(53%). 
 
3.1.2 Cohort 2 – Mutation positive  (n = 15) 
Thirteen patients had mutations of the MLH1 gene and two had mutations of the 
MSH2 gene (Appendix 4).  The patients’ ages ranged from 29 to 50 years, with a 
mean age of 42.8 years.  The gender distribution was near equal and similar to 
cohort 1.  The tumours were frequently seen in the right colon (75%).  All of the 
adenocarcinomas, NOS were low grade and 9 (60%) cases demonstrated 
mucinous differentiation (Figure 3B). In addition, tumour infiltrating 
lymphocytes were most frequent in this cohort (33%) (Figure 3F).  All except 
one tumour had an expanding tumour edge (Figure 3C) and a Crohns like 
reaction was present in 53% of cases (Figure 3E).  Only 3 cases demonstrated 
synchronous tumours.  The majority of the cases were stage III (53%). 
 
3.1.3 Cohort 3 – Sporadic  (n = 28) 
The patients’ ages ranged from 53 to 83 years, with a mean age of 67 years.  
There were 15 males and 13 females.  The tumours were frequently seen in the 
left colon (54%), followed by the rectum (32%) and then the right colon (14%).  
Again, as in cohort 1, the adenocarcinomas, NOS were predominantly low grade 
(95%) (Figure 3A).  However, mucinous differentiation was seen in 32% of 
cases.  Again both infiltrating (57%) (Figure 3D) and expanding margins (43%) 
were noted.  A Crohns like reaction was seen in 43% of cases and tumour 
infiltrating lymphocytes were infrequent (7%).  The majority of the cases were 
stage III (46%). 
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Figure 3: Histopathological features of colorectal adenocarcinomas, (A) Low 
grade colorectal adenocarcinoma, NOS 40x obj mag, (B) Mucinous 
adenocarcinoma 40x obj mag, (C) Circumscribed pushing border 2.5x obj mag, 
(D) Infiltrating border 4x obj mag, (E) Crohns like reaction 2.5 obj mag and (F) 
Tumour infiltrating lymphocytes 40x obj mag in medullary carcinoma. 
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3.1.4 Immunohistochemical analysis 
3.1.4.1 p21  
Figure 4: p21 immunohistochemistry:  (A) 1+ intensity 40x obj mag, in a low 
grade adenocarcinoma, (B) 2+ intensity 40x obj mag in the solid component of a 
mucinous adenocarcinoma and (C) 3+ intensity 40x obj mag in a low grade 
conventional adenocarcinoma 
The expression of p21 was localised to the nuclei and the intensity of staining was 
variable (Figure 4A to C).  The stromal cells and the epithelial cells were 
negative in the majority of cases.  The tumours showed marked intratumoural 
heterogeneity, with very limited expression in the 3 cohorts.  Fifty one of the 60 
cases were completely negative with only 9 positive cases, of which three were 
mucinous adenocarcinomas and the rest low grade conventional 
adenocarcinomas, NOS.  Two of the cases were stage I tumours, 2 cases were 
stage II tumours and 5 were stage III adenocarcinomas.   
A 
C 
B 
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 There was no statistical significance for p21 expression among the three cohorts 
(Kruskal –Wallis equality-of-populations rank test, P=0.5209).  
There was no statistical significance in p21 expression and stage in cohort 1 
(P=0.8811), cohort 2 (P=0.3499) and cohort 3 (P=0.8235).  
There was no statistical significance in p21 expression and  tumour type in cohort 
1  (P=0.4230), cohort 2 (P=0.8204) and cohort 3 (P=0.5261) . 
 
3.1.4.2 p27 
  
 
 
Figure 5: p27 immunohistochemistry: (A) 1+ intensity of nuclear expression 40x 
obj mag, (B) 2+ intensity of nuclear expression 40x obj mag and (C) 3+ intensity 
of nuclear and cytoplasmic expression 40x obj mag in 3 low grade conventional 
adenocarcinomas, NOS 
 
Expression of p27 was localised in the nucleus with occasional cytoplasmic 
expression (Figure 5A to 5C).  All of the tumours stained positive for p27.  The 
background lymphocytes were also diffusely positive and the normal mucosal 
A 
C 
B 
42 
 
epithelium showed greater heterogeneity of staining than the invasive tumour. 
These served as inbuilt controls.  
There was no statistical significance for p27 expression among the three cohorts 
(Kruskal –Wallis equality-of-populations rank test, P=0.3048).   
There was no statistical significance in p27 expression and stage in cohort 1 
(P=0.5036), cohort 2 (P=0.5415) and cohort 3 (P=0.5641) .  
There was no statistical significance in p27 expression and  tumour type in cohort 
1  (P=0.7812), cohort 2 (P=0.3186) and cohort 3 (P=0.4086) . 
3.1.4.3  p53 
Figure 6: p53 immunohistochemistry: (A) 1+ intensity 40x obj mag, (B) 
2+intensity 40x obj mag and (C) 3+ intensity 40x obj mag in 3 low grade 
conventional adenocarcinomas, NOS 
p53 was expressed in the nuclei of the malignant cells (Figure 6A to 6C).  There 
was no statistical significant difference in p53 expression among the 3 cohorts 
(Kruskal –Wallis equality-of-populations rank test, P=0.3652).  One case was 
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negative in each of the mutation positive and mutation negative cohorts, while ten 
cases were negative in the sporadic cohort.  Interestingly, the highest scores were 
recorded in the mutation negative and sporadic cohorts with 9/17 and 13/28 
scoring an H-score of 12 respectively, in contrast only 3/15 cases scored a total of 
12 in the mutation positive cohort.  
 
There was no statistical significance in p53 expression and stage in cohort 1 
(P=0.5693), cohort 2 (P=0.4046) and cohort 3 (P=0.6583).  
There was no statistical significance in p53 expression and tumour type in cohort 
1 (P=0.1934), cohort 2 (P=0.7692) and cohort 3 (P=0.3580) . 
 
If one considered wild type staining as the expression in less than 50% of cells 
(i.e proportion 1 and 2) and mutant p53 as more than 50% expression in the cells 
(i.e. proportions 3 and 4) in the 3 cohorts, the results are as follows: 
 
It appears the mutation negative cohort has the most cases with mutant p53 
expression, with 76% of the cases positive, followed by the mutation positive 
cohort (53%) and then the sporadic cohort of tumours (50%). 
 
3.1.4.4  Cyclin D1 
Cyclin D1 demonstrated heterogeneous nuclear staining in most cases, with 
varying intensities (Figure 7A to 7C).  On further analysis, the difference in 
cyclin D1 expression was statistically significant between the mutation positive 
and mutation negative cohorts, with a P=0.0024 (Two-sample Wilcoxon rank-
sum test).  There were no statistical differences between the mutation positive and 
the sporadic cohorts (Two-sample Wilcoxon rank-sum test – p=0.0343) and the 
mutation negative and sporadic cohorts (Two-sample Wilcoxon rank-sum test – 
P=0.1347).  All the mutation positive cases expressed some degree of cyclin D1 
compared with 8/28 sporadic cases and 10/17 mutation negative cases being 
 Negative  Wild-type p53  Mutant p53  
Cohort 1 (n=17) 1 3 13 
Cohort 2 (n=15) 1 6 8 
Cohort 3 (n=28) 10 4 14 
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completely negative. In addition, of all the cyclin D1 negative cases i.e. 18/60 
cases, 11 were also negative for cyclin E. 
  
 
 
Figure 7: Cyclin D1 immunohistochemistry: (A) 1+ intensity 40x obj mag (B) 2+ 
intensity 40x obj mag and (C) 3+ intensity 40x obj mag in 3 low grade 
conventional adenocarcinomas, NOS  
 
There was no statistical significance in cyclin D1 expression and stage in cohort 1 
(P=0.1202), cohort 2 (P=0.7204) and cohort 3 (P=0.9986).  
There was no statistical significance in cyclin D1 expression and tumour type in 
cohort 1 (P=0.2409), cohort 2 (P=0.3482) and cohort 3 (P=0.1594) . 
 
3.1.4.5  Cyclin E 
Cyclin E demonstrated heterogeneous nuclear staining in most cases, with 
intensities as illustrated in Figure 8A to 8C.  Cyclin E expression was statistically 
significant only between the mutation positive and the sporadic cohort (P=0.0012, 
Two-sample Wilcoxon rank-sum test). 
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There were no statistically significant differences in expression between mutation 
positive and mutation negative cohorts (Two-sample Wilcoxon rank-sum test – 
P=0.232) and mutation negative and sporadic cohorts (Two-sample Wilcoxon 
rank-sum test – P=0.2612). 
Again, the majority of the mutation positive cases 13/15 were immunoreactive for 
cyclin E.  There were 17/28 cases in the sporadic cohort and 7/17 cases in the 
mutation negative cohort that were completely negative. 
Figure 8:  Cyclin E immunohistochemistry: (A) 1+ intensity 40x obj mag, (B) 2+ 
intensity 40x obj mag in an adenocarcinoma, NOS and (C) 3+ intensity 40x obj 
mag in 3 conventional adenocarcinomas, NOS 
There was no statistical significance in cyclin E expression and stage in cohort 1 
(P=0.2738), cohort 2 (P=0.3936) and cohort 3 (P=0.4986).  
There was no statistical significance in cyclin E expression and tumour type in 
cohort 1 (P=0.4829), cohort 2 (P=0.4880) and cohort 3 (P=0.1978) . 
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3.1.4.6  C-myc 
Figure 9: C-myc immunohistochemistry: (A) Normal tonsil control 
demonstrating nuclear and occasional cytoplasmic staining in lymphocytes and 
(B) granular cytoplasmic staining of the malignant cells in a low grade 
conventional adenocarcinoma, NOS. Nuclei are negative. 
No nuclear expression was seen in any of the nuclei of the 60 cases examined. 
However, cytoplasmic granular staining (Figure 9) of varying intensities was 
seen.  This included 8/17 cases (47%) in cohort 1, 9/15 cases (60%) in cohort 2 
and 17/28 cases in cohort 3 (61%).  Since only nuclear staining was considered 
positive, no statistical analysis was done as the exact significance was uncertain.  
Although nuclear staining was observed in lymphocytes in the tonsil control 
tissue, cytoplasmic staining with peri-nuclear accentuation was also noted in 
lymphocytes. 
. 
3.1.4.7  MMP-7 
A fine to coarse granular staining was noted in the cytoplasm of the malignant 
cells (Figure 10).  There was no staining in the stromal fibroblasts.  There was no 
statistical significance for MMP-7 among the three cohorts (Kruskal –Wallis 
equality-of-populations rank test, p=0.6587). 
There was no statistical significance in MMP-7 expression and stage in cohort 1 
(P=0.5305), cohort 2 (P=0.2703) and cohort 3 (P=0.8950).  
There was no statistical significance in MMP-7 expression and tumour type in 
cohort 1 (P=0.9372), cohort 2 (P=0.8204) and cohort 3 (P=0.6289) . 
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Figure 10: MMP-7 immunohistocemistry (A) 1+ intensity 40x obj mag, (B) 
2+intensity 40x obj mag and (C) 3+ intensity 40x obj mag in three low grade 
conventional adenocarcinomas, NOS 
Figure 11: Invasive tumour margin in a low grade adenocarcinoma, NOS 
demonstrating increased MMP-7 immunoexpression with accentuation at the 
infiltrating edge.  
TM 
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There was a variation in staining at the invasive tumour margin (Figure 11).  The 
staining was either uniform, increased or in a few cases decreased at the invasive 
margin (Table 5).  In addition, the cytoplasmic staining appeared much coarser at 
the invasive front when increased.  This was assessed away from the edge of the 
tissue sections as far as possible to avoid artefactual increase in staining (edge 
artefact). 
 
Table 5: Staining of MMP-7 at invasive tumour margin 
 Increased staining at 
tumour margin 
Decreased staining at 
tumour margin 
Uniform staining 
throughout the tumour 
Cohort 1 (n=17) 8 0 9 
Cohort 2 (n=15) 5 1 9 
Cohort 3 (n=28) 15 2 11 
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3.1.4.8 MLH1 
Figure 12: MLH1 immunohistochemistry: (A) Nuclear expression in the 
malignant glands 10x obj mag of a low grade adenocarcinoma, NOS, (B) loss of 
expression in the solid component of a mucinous carcinoma, note the positive 
internal control in stromal cells and lymphocytes 40x obj mag and (C) loss of 
expression in a low grade adenocarcinoma, NOS with positive TILs in a mutation 
positive case 40x obj mag.  
In the negative cases, the background stromal cells, lymphocytes and normal 
glandular epithelial cells were positive (Figure 12).  In cases, where there was an 
increase in tumour infiltrating lymphocytes, the positive MLH1 staining served as 
a good marker for the lymphocytes, making it easier to count.  
All 13 cases that showed MLH1 mutations were negative for MLH1 
immunohistochemistry, a 100% concordance.  In contrast, a smaller percentage of 
cases in the mutation negative and sporadic cohorts showed loss of MLH1.  This 
was statistically significant between the mutation positive cohort and the sporadic 
cohort (P<0.0001) as well as between the mutation positive cohort and the 
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mutation negative cohort (P<0.0001).  There was no statistical significance 
between the mutation negative cohort and the sporadic cohort (P=0.0676).  
Only five cases were negative for MLH1 immunoexpression in our cohort of 
sporadic CRCs.  The interesting findings were that all five of the MLH1 negative 
tumours were on the right side of the colon and all were special subtypes, i.e. 2 
mucinous, 1 signet ring cell, 1 medullary and 1 serrated adenocarcinoma.  All the 
mutation negative cases expressed MLH1 by immunohistochemistry (17/17). 
3.1.4.9 MSH2 
Figure 13: MSH2 immunohistochemistry: (A) Nuclear expression in the 
malignant glands 10x obj mag of a low grade adenocarcinoma, (B) a low grade 
adenocarcinoma showing loss of expression, note positive internal control in 
stromal cells and lymphocytes 40x obj mag  
Tumours that were negative for MSH2 immunohistochemistry showed positive 
inbuilt controls similar to that of MLH1 (Figure 13B).  There was no statistical 
difference in MSH2 immunoexpression among the three cohorts. 
Two cases in the sporadic cohort were indeterminate as both tumour and inbuilt 
controls were negative, and were not included in the statistical analysis.  The 
indeterminate cases were re-stained and remained indeterminate.  The negative 
case was a serrated adenocarcinoma, where all three MMR markers were 
negative.  In the latter case the following cell cycle regulators were positive: p27, 
cyclin D1 and cyclin E. 
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There were 3 cases from the mutation positive cohort that were negative.  Of the 3 
cases, 2 were positive for MLH1 and both were negative for MSH6.  These two 
cases had confirmed MSH2 mutations.  The third case was a stage 3 mucinous 
carcinoma and negative for all three markers.   
The mutation negative cohort had three cases which were negative for MSH2 
only (i.e. these cases expressed both MLH1 and MSH6), 2 were from the right 
colon with conventional adenocarcinoma histology and the third was from the left 
colon, with high grade histology and tumour infiltrating lymphocytes. 
3.1.4.10  MSH6 
Figure 14: MSH6 immunohistochemistry: (A) A positive low grade 
adenocarcinoma, NOS demonstrating nuclear staining 10x obj mag and (B) an 
MSH6 negative low grade adenocarcinoma, NOS 40x obj mag. 
Of the 60 cases, 3 were indeterminate and were excluded from the statistical 
analysis.  There was no statistically significant difference in expression among the 
3 cohorts. 
The mutation negative cohort showed 16/17 positive cases, with 1 case being 
indeterminate.  There were 6 cases in the mutation positive cohort which did not 
express MSH6 on immunohistochemistry:  3 negative MLH1 cases, 2 negative 
MSH2 cases and 1 case negative for both MSH2 and MLH1.  
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In the sporadic cohort, there were 3 cases which were negative and a further 2 
cases were indeterminate.  Of the 3 negative cases, one case was negative for 
MLH1 only and the second case negative for both MLH1 and MSH2 while the 
third case was positive for MLH1 but the MSH2 was indeterminate.  Of the 2 
indeterminate cases, 1 was positive for MLH1 and indeterminate for MSH2 while 
the second case was positive for MLH1 and MSH2.  All indeterminate cases were 
re-stained but there was no change in the expression, normal and tumour cells 
were still completely negative. 
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CHAPTER 4 
 
4. DISCUSSION 
4.1 Clinical and Morphological Features 
The mutation positive cases (cohort 2) showed a predominance of right sided 
tumours, more frequent mucinous differentiation, Crohns like reaction and tumour 
infiltrating lymphocytes, in keeping with previously published findings (17, 44). 
Of all the parameters described, tumour infiltrating lymphocytes and an 
expanding/“circumscribed” margin was more predominant in cohort 2 when 
compared to the other cohorts, which may contribute to the improved prognosis in 
HNPCC patients.  The lymphocytes are usually cytotoxic T lymphocytes, which 
are associated with tumour cell apoptosis but these were not tested for in our 
study (13).  A study by Greenson et al, which investigated 52 microsatellite 
unstable tumours, found that TILs were the best predictor for microsatellite 
unstable tumours.  In addition, the absence of “dirty necrosis” and/or focal 
mucinous differentiation together with TILs identified all 52 tumours in that 
study, which showed morphology to be 100% sensitive (45).  Although mucinous 
tumours that are MSI-H have a better prognosis than MSI-L and MSS mucinous 
CRCs (2), there was no correlation with the cell cycle regulators and MMP-7 
when compared with the tumour type in each patient cohort.  This may be the 
result of the low numbers of mucinous adenocarcinomas in the cohorts.  
 
The patients in cohort 1 (younger than 50 years and mutation negative) also 
demonstrated a predominance of tumours on the right side of the colon but less 
than that of the mutation positive cases.  The morphology in this cohort was 
similar to that of the sporadic cohort, with no significant differences.  However, 
this cohort had the youngest mean age of 38 years, which suggests a possible 
underlying germline mutation. 
 
Overall, the mutation negative cases appeared to have similar morphological 
profiles to the sporadic cohort, with the only major discrepancies being tumour 
site and Crohns like reaction.  The latter can be quite subjective as the literature 
suggests, because criteria are not well defined in studies. 
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In the sporadic cohort, the interesting finding was that all 5 adenocarcinomas that 
tested negative for MLH1 immunohistochemistry were special subtypes, all 
associated with MSI-H tumours.  Therefore, histology of the colorectal 
carcinomas may be important in screening for possible MSI-H tumours.   
 
The majority of tumours in all three cohorts showed low grade histology and 
stage III tumours, with nodal metastasis seen in 59% (mutation negative), 53% 
(mutation positive) and 50% (sporadic) of the cases. 
 
4.2 Cell cycle inhibitors – p21, p27 and p53 
The immunoexpression of p21, p27 and p53 did not show statistical significance 
among the three cohorts.  p21 expression was downregulated in all three cohorts, 
with only 10 of  the 60 cases (18%) demonstrating some degree of positivity 
among the cohorts.  The downregulation of p21 is usually associated with 
mutations in p53.  A study by Sinicrope et al demonstrated a significant reduction 
of p21 in sporadic colorectal carcinoma when compared to HNPCC cases, with 
80% of cases (12/15 cases) retaining p21 expression (46).  Their findings were 
attributed to a possible inverse relationship to p53 i.e. mutant p53 was seen in 
27% of the HNPCC cases and 69% of the sporadic cases compared to p21 seen in 
31% of sporadic CRCs and 80% of HNPCC cases.  Similar findings were also 
seen in MSI-H tumours compared to MSS tumours in a study by Edmonston et al 
(47).  In another study of a Danish population of HNPCC patients, upregulation of 
p21 was present with down regulation of p53 (48). 
 
The findings of our study do not support the inverse relationship of p21 and 
mutant p53 in the mutation positive cohort (cohort 2) i.e. there was no significant 
p21 expression and 53% of all cases expressed mutant p53.  There was a 
reduction in p21 expression in all three cohorts compared to p53.  In our study 
cohort, of the 8 cases that expressed p21, 7 had also expressed p53, suggesting an 
alternative pathway of activation of p21, this is similar to that described in the 
literature (49, 50).  Two other factors WISp39 and Hsp90 have been shown to 
regulate p21 (51).  An alteration of any one of these factors causes 
downregulation of p21, irrespective of the presence of wild-type p53.  
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Antibodies can detect both mutant and wild type p53 and since wild-type p53 has 
low detection levels and a short half-life, most p53 antibodies are able to detect 
abnormal p53 (52).  If one had to consider staining of p53 in less than 50% of 
cells as wild-type staining (52), then the sporadic tumours have the least 
expression of p53 (43%) from the three cohorts with a 10% difference from the 
mutation positive cohort (53%).  This finding is different from the studies 
mentioned above (47, 48) and a further study which demonstrated decreased p53 
gene mutations in HNPCC patients which was much lower than the sporadic 
tumours (53). However, there is also a study in the literature demonstrating no 
statistical significance in p53 staining between sporadic (70 cases) and HNPCC 
(46 cases) CRCs (54). 
 
The p27 immunohistochemical marker was positive in all 60 cases, suggesting an 
upregulation in CRCs, independent of p53 and p21.  Other studies have revealed 
high levels of p27 expression in lower-stage CRCs compared to low levels of p27 
in advanced stage CRCs.  Our study showed no significance in p27 expression 
between the three cohorts and findings are similar to that seen in a study by 
Edmonston et al (47). 
 
Overall, there was no significant correlation of the cell cycle inhibitors (p21, p27 
and p53) with tumour type and stage in all three cohorts. 
 
4.3 C-myc  
The proto-oncogene c-myc is thought to act through the nucleus.  C-myc did not 
show any nuclear staining in any of the three cohorts, which was considered 
significant.  However, some cases did demonstrate granular cytoplasmic staining 
(different intensities) of uncertain significance.   
 
Cytoplasmic expression has been described in other tumours like aggressive 
lymphomas (55).  Royds et al demonstrated pancytoplasmic staining of c-myc in 
colorectal carcinomas (compared to adenomas), with decreased nuclear staining. 
In that study, confirmation of c-myc in the cytoplasm was accomplished using 
electron microscopy which showed binding to polyribosomes (56).  The features 
suggested that alterations in the C-terminus allowed for accumulation of c-myc in 
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the cytoplasm because of ineffective binding to the nucleus.  Another study 
demonstrated that subcellular localization was highly dependent on the type and 
timing of tissue fixation.  They found that in frozen tissue c-myc expression 
localised to the nucleus while the same tissue following formalin fixation showed 
loss of nuclear staining (57).  However, the antibodies were not validated.  Some 
of the tissues in our study did date back to the 1980s and showed comparable 
staining to more recent cases, confirming that protocols for fixing excision 
specimens have remained constant in our laboratory. 
 
4.4 Cyclins D1 and E 
Cyclins D1 and E were both increased in the mutation positive cohort.  When 
expression in the mutation positive cohort was compared to the other cohorts, 
only cyclin E demonstrated a statistical difference with the sporadic cohort and 
cyclin D1 with the mutation negative cohort.  Overall, since the cell cycle has to 
be activated in all three cohorts for cells to proliferate, the expression of both 
cyclins should be increased, in theory.  It appears the mutation negative cohort 
preferentially expresses cyclin E and the sporadic cohort preferentially expresses 
cyclin D1 at the expense of the other cyclin in our study.  Overall, the 
combination of cyclins were activated in 49 cases with 11 cases negative for both 
cyclin D1 and cyclin E.   
 
In a Danish study population of 34 HNPCC CRCs, both cyclins D1 and E 
expression were significantly increased in 68% and 32% of cases, respectively 
(48).  However, overexpression of p53 and p21 was found in 21% and 71% of the 
study cases respectively, the reverse of what was seen in our study population.  
Since p21 regulates the cyclins, one would expect expression of cyclin D1 and E 
to be increased.  However, p21 expression was decreased in our study and p27 
was upregulated which inhibits cyclin E.  Therefore other factors involved in the 
regulation of the cell cycle and Wnt signalling pathway may be implicated in the 
expression of the cyclins. 
 
The mutation in the APC gene allows for accumulation of β-catenin within the 
cell, which in turn activates cyclin D1 and cyclin E (58).  Therefore increased 
expression of cyclin D1 and cyclin E is expected with APC mutations as seen in 
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sporadic CRCs.  However, increased frequency of CTNNB1 mutations (encodes 
β-catenin) have been described in patients with MSI-H and HNPCC (59, 60).  In 
addition, APC mutations have also been reported in HNPCC CRCs but with much 
less frequency when compared to sporadic tumours (60).  These HNPCC tumours 
with CTNNB1 mutations demonstrated β-catenin accumulation in the nuclei of 
tumour cells with immunohistochemistry.  Overall this suggests that the Wnt-
pathway still plays a major role in carcinogenesis irrespective of the MSI status, 
as seen in this cohort of patients and described in the literature (59, 60). 
 
The elevated expression of cyclin E in the mutation positive cohort may be linked 
to downregulation of the FBXW7 gene in this cohort.  However, a study by 
Miyaki et al did not demonstrate appreciable difference in FBXW7 gene 
mutations between HNPCC and sporadic cases of CRCs (61).  In addition, 
another study showed that low expression of mRNA FBXW7 was associated with 
a poor prognosis compared to the high expression group.  This is contradictory to 
HNPCC patients in general, where the patients have a good prognosis (62). 
Therefore increases in cyclin E expression together with cyclin D1 may be linked 
to aberrations in the Wnt pathway.  There are limited studies with cyclin E and 
HNPCC in the literature, and the activation of this cell cycle regulator needs to be 
explored further. 
 
Finally, there was no statistically significant correlation of cyclin D1 and cyclin E 
with tumour type and stage in all 3 cohorts. 
 
4.5 MMP-7 
MMP-7 is linked to increased frequency of metastasis in CRCs in some studies 
(36, 63).  In our study there was no appreciable difference in MMP-7 expression 
among the three cohorts and there was no statistically significant difference 
between MMP-7 expression and stage of tumour.  
 
MMP-7 is a target gene of the Wnt pathway and the expression of β-catenin and 
MMP-7 is correlated in CRCs (64).  MMP-7 allows for the breakdown of the E-
cadherin-β-catenin complex, allowing β-catenin to accumulate in the cytoplasm.  
A recent study of epithelial mesenchymal transition demonstrated that the 
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expression of β-catenin, mismatch repair proteins, E-cadherin, MMP-7, TGFβRII 
and tissue inhibitors of metalloproteinases-2 (TIMP-2) was significantly 
associated with depth of invasion and metastasis (64).  Unfortunately, we were 
unable to investigate β-catenin immunoexpression because of limited funding.  
Gu et al also demonstrated lower expression levels of hMSH2, hMLH1, 
cytoplasmic β-catenin, TGFβRII and MMP-7 with higher levels of E-cadherin, 
TIMP-2 and membrane β-catenin in HNPCC tumours when compared to sporadic 
CRCs.  In another gene microarray study, 11 microsatellite unstable tumours, 
demonstrated dowregulation of the MMP-7 gene when compared to MSI-L and 
MSS tumours (65).  
 
The β-catenin that accumulates following mutations in the APC gene in sporadic 
CRCs, results in accumulation of cytoplasmic β-catenin and increasing expression 
of MMP-7, resulting in invasion and metastasis.  However in HNPCC, mutations 
in TGFβRII seen especially with MLH1 and MSH2 mutations, reduces the ability 
of the E-cadherin and plasma membrane β-catenin to disassemble, so that plasma 
membrane β-catenin increases in HNPCC CRCs (64).  This may explain the better 
prognosis and fewer metastases in Lynch syndrome patients. 
 
Our study did not reveal a significant decrease in expression of MMP-7 in the 
mutation positive cohort and no statistical differences were seen among the three 
cohorts or when compared to the stage in the individual cohorts.  Although our 
study number was small, most of the cases demonstrated uniform staining in the 
mutation positive cohort i.e. 9 cases (60%).  Uniform staining was also seen in 
53% of the mutation negative cases and 39% of the sporadic cases.  All the cases 
(n=60) expressed MMP-7, which allows for the tumour cells to invade and 
breakdown the stroma.  Also, nodal metastases were seen in 5 cases (33%) in the 
mutation positive cohort.  The increase in expression at the tumour margins is 
interesting, as there appears to be some “ordered communication” of the 
malignant cells at the tumour edge, allowing for tumour progression.  The 
“microenvironment” at the edge of the tumour may possibly be disrupted by TILs 
(secreting interleukins), decreasing tumour progression.    
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4.6 Mismatch repair proteins – MLH1, MSH2 and MSH6 
MLH1 demonstrated significant differences in expression among the three 
cohorts.  There was a strong concordance of MLH1 loss on 
immunohistochemistry and MLH1 mutation positive tumours.  Groote Schuur 
hospital offers a screening service to the Kleinsee population with our laboratory 
receiving the specimens.  MLH1 is by far the commonest mutation seen in 
numerous studies (44).   
 
The sporadic tumours in our cohort that were MLH1 negative were all special 
subtypes of adenocarcinoma that are also seen in HNPCC and MSI-H cases.  
These possible sporadic MSI-H tumours may be the result of hypermethylation of 
DNA and BRAF mutations, which are commonly seen in sporadic MSI tumours, 
and also being more common in female patients.  Of these 5 sporadic cases in our 
cohort, 4 were female patients.  However, one should not completely rule out a 
case of HNPCC in patients over 50 years.  Some patients can have late-onset 
CRCs in Lynch families (>50 years) (66). 
 
The MLH1 immunoexpression in the mutation positive cohort was consistent 
with that of the germline analysis in that all cases that showed loss of 
immunoexpression tested positive for MLH1 mutations (Appendix 3).  The two 
cases that tested negative for MSH2 also demonstrated mutations in the MSH2 
gene.   
 
The 2 cases that were negative for MSH2 were also negative for MSH6 and 
positive for MLH1 in the mutation negative cohort.  This could be consistent with 
MSH2 mutations not tested in our centre, rare MSH6 mutations or mutations 
involving factors or proteins controlling expression of the MSH2 gene.  There was 
a single case that was negative for all three MMR proteins.  Our findings are 
consistent with Rigau et al who conducted a meta-analysis of MMR proteins to 
assess MSI in 11 series and found that using only 2 antibodies, MLH1 and MSH2 
allowed for a diagnosis of MSI with high sensitivity and specificity (44).  
 
Mutations in MSH6 and PMS2 are seen in rare cases of HNPCC.  Our cohort 
showed 6 cases negative for the MSH6 protein in the mutation positive cohort.  
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Of the 6 cases, three were associated with loss of MLH1 and intact MSH2, two 
were associated with loss of MSH2 and one was associated with loss of all three 
proteins.  The 2 cases associated with loss of MSH2 can be explained by the 
MSH2 mutations, since there is heterodimeric pairing of the MMR proteins i.e. 
MSH2 forms a complex with MSH6, so if one is mutated, the other is degraded.  
The loss of both these proteins has also been well documented in other studies 
(67, 68).  However, the loss of both MLH1 and MSH6 would be unusual, since 
these two proteins do not form a complex.  The full mutational analysis of all four 
MMR genes for these three tumours and the tumour with all three markers 
negative would be useful to determine which results are truly negative.  In the 
sporadic cohort, two cases were negative for MSH6, the first a serrated 
adenocarcinoma demonstrating loss of all three markers.  This suggests 
hypermethylation of the DNA resulting in downgrading of all three proteins.  The 
other case was a conventional adenocarcinoma, with only MSH6 loss and an 
indeterminate MSH2 expression. 
 
In this study, we were limited to three MMR markers rather than four markers 
which includes PMS2.  This was based on the recommendations of Rigau et al 
(44) and the known heterodimeric complexes formed by MLH1 and PMS2, so 
that if there is inactivation of the one protein, there is usually decreased 
expression of the other. 
 
4.7 Limitations 
Finally, some of the drawbacks of this study included low case numbers in 
cohorts 1 and 2.  This was due to the limited excision specimens that were less 
than 50 years with and without proven MMR gene mutations in our database.  
Another factor was the non-availability of tissue blocks for many of the mutation 
positive cases where surgery was done at other hospitals.   
 
Furthermore, there was limited or no survival data available for the majority of 
patients in all the cohorts.  This limited the outcome analysis to tumour stage.  
Grade of tumour, could not be used as a reliable prognostic variable as there were 
only two cases with high grade histology in all 60 cases. 
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Pre-analytic variables regarding optimal fixation of CRC excision specimens in 
formalin, may have had an influence on the expression of immunohistochemical 
markers and also needs to be taken into consideration.  In this laboratory 
colorectal resection specimens are usually opened, fixed in formalin overnight 
and then processed the next day.  All of the cases demonstrated staining in one or 
more of the immunohistochemical markers in this study, implying intact tissue 
integrity.  The immunohistochemical markers themselves have their own 
sensitivities and specificities which was accounted and optimised for in the 
protocol.  
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CHAPTER 5 
 
5.  Conclusion  
 
Although major advances have been made in the various pathways of colorectal 
carcinogenesis, it still remains complex, with various interactions at the molecular 
level. 
  
Overall, there were statistically significant differences between the mutation 
positive and both the sporadic and mutation negative cohorts with respect to 
morphology and MLH1 immunoexpression.  The morphological features included 
TILs, expanding margin, Crohns like reaction and mucinous differentiation.  
These features in combination can be helpful in identifying MSI-H tumours and 
cases requiring further molecular studies.  In our population, MLH1 mutations are 
the commonest. 
 
This study found that cell cycle markers were unlikely to be solely or 
independently responsible for the differences in behaviour and prognosis of 
HNPCC CRCs versus sporadic CRCs.  Overall, the cyclins are increased in all 
three cohorts, the upregulation dependent on cell cycle regulators and factors in 
the Wnt signalling pathway.  Cyclin D1 showed some difference in 
immunoexpression between the mutation positive and negative cohorts and cyclin 
E between the mutation positive and sporadic cohorts.  The mutation negative 
cohort preferentially expressed cyclin E and the sporadic cohort preferentially 
expressed cyclin D1, with both these cell cycle markers upregulated in the 
mutation positive cohort.  Overall, the cell cycle markers did not explain the 
improved prognosis of the mutation positive cohort.  The cell cycle regulators and 
MMP-7 did not show any significant correlation with tumour stage or tumour 
type in the three cohorts. 
 
It is worth further exploring the expression of MMP-7 in CRCs to determine 
whether distribution of expression has any significance on invasiveness and 
metastatic potential of the primary neoplasm. 
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Overall, the mutation negative cohort in our population continues to remain 
enigmatic and further testing at the molecular level is required, that may reveal 
another novel pathway of colorectal carcinogenesis or other novel mutations in 
mismatch repair genes.  Since only tests for mutations in MLH1 and MSH2 are 
only available at our centre, some of these cases could still harbour a mutation in 
another MMR gene.  
 
This study has raised the possibility that the Wnt signalling pathway may have a 
more integral role in CRC behaviour.  Further investigation of this pathway in 
relation to the MMR profile is warranted. 
 
The complex intracellular signalling pathways most likely hold the key to 
understanding and predicting CRC behaviour and prognosis.  Furthermore, 
identifying some of these key biomarkers may lead to new therapeutic 
interventions, such as, targeted therapy. 
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 APPENDICES 
 
KEY: 
 
ADENO Adenocarcinoma, NOS 
ASSOC POLYP Associated Polyps 
CONFIG Configuration 
CROHNS Crohns like reaction 
E Expanding 
G Gender 
GD Greatest dimension 
HS H-score 
I Intensity 
If Infiltrating 
IN Indeterminate 
M Distant metastases 
MC Mucinous component 
MN Mutation negative 
MP Mutation positive 
N Nodes involved 
Neg Negative 
NR Not recorded 
P Proportion 
PERF Perforation 
Pos Positive 
S Sporadic 
T Tumour size 
TIL Tumour infiltrating lymphocytes 
TM Tumour Margin 
X Unknown 
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Appendix 1: Cohort 1 (Mutation negative) Morphological features 
 
 CASE  G AGE SITE GD CONFIG PERF 
ASSOC 
POLYP TYPE GRADE TIL CROHNS TM T N M STAGE 
MN1 M 25 RIGHT 50 ANN,CONST YES YES ADENO LOW NO YES E 4 1 X 3 
MN2 F 41 LEFT 35 EXOPHYTIC NO NO ADENO LOW NO YES E 3 1 X 3 
MN3 M 37 RIGHT 55 EXOPHYTIC NO NO MUCINOUS    NO NO If 2 1 X 3 
MN4 F 34 RECTUM 60 ANN,CONST NO NO ADENO HIGH YES NO E 4 0 X 2 
MN5 M 35 RIGHT 40 ANN,CONST NO YES ADENO LOW NO NO In 4 1 X 3 
MN6 M 40 RECTUM 14 ULCERATED NO NO ADENO LOW NO NO E 3 1 X 3 
MN7 M 42 RECTUM 55 NR NO NO MUCINOUS    NO NO E 3 2 X 3 
MN8 F 44 LEFT 28 ULCERATED YES NO ADENO LOW NO NO If 4 1 1 4 
MN9 F 43 RECTUM 60 ANN,CONST NO NO ADENO LOW NO NO If 3 0 X 2 
MN10 M 36 RIGHT 80 ANN,CONST YES NO ADENO LOW NO NO In 2 1 X 3 
MN11 M 37 RIGHT 50 ANN,CONST NO NO ADENO LOW NO YES E 3 0 X 2 
MN12 F 33 
RIGHT and 
LEFT 100,43 ANN,CONST NO NO ADENO LOW NO NO E 4 1 X 3 
MN13 M 36 RIGHT 80 EXOPHYTIC NO NO ADENO LOW NO YES If 3 0 X 2 
MN14 M 49 RECTUM 50 ULCERATED NO NO ADENO LOW NO NO If 1 0 X 1 
MN15 F 36 RIGHT 60 ULCERATED NO NO ADENO LOW NO NO If 1 0 X 1 
MN16 F 46 RECTUM 80 EXOPHYTIC NO NO ADENO LOW NO NO In 3 2 X 3 
MN17 F 36 LEFT 40 EXOPHYTIC NO NO ADENO LOW NO YES E 3 0 X 2 
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Appendix 2: Cohort 1 (Mutation negative) Immunohistochemical results 
 
 CASE  P21 P27 CYCLIN D1 CYCLIN E p53 c-myc MMP7 MLH1 MSH6 MSH2 
  P I HS P I HS P I HS P I 
H
S P I HS P I CYT P I HS       
MN1 0 1 0 2 2 4 0 0 0 0 0 0 4 3 12 0 0 Pos 4 2 8 Pos Pos Pos 
MN2 0 0 0 3 2 6 0 0 0 0 1 0 4 3 12 0 0   4 2 8 Pos IN Pos 
MN3 0 0 0 3 3 9 0 1 0 0 1 0 4 3 12 0 0 Pos 2 1 2 Pos Pos Pos 
MN4 0 0 0 4 2 8 0 2 0 1 1 1 2 3 6 0 0 Pos 4 3 12 Pos Pos Neg 
MN5 0 2 0 4 2 8 0 1 0 0 0 0 0 0 0 0 0   4 3 12 Pos Pos Pos 
MN6 0 1 0 4 3 12 0 1 0 0 0 0 4 3 12 0 0   4 2 8 Pos Pos Pos 
MN7 0 0 0 4 3 12 0 2 0 1 1 1 4 3 12 0 0 Pos 4 3 12 Pos Pos Pos 
MN8 0 0 0 4 3 12 0 2 0 1 1 1 4 3 12 0 0 Pos 4 2 8 Pos Pos Pos 
MN9 0 0 0 4 3 12 0 1 0 1 1 1 4 3 12 0 0   2 1 2 Pos Pos Pos 
MN10 1 3 3 4 3 12 0 1 0 3 1 3 3 2 6 0 0   4 2 8 Pos Pos Pos 
MN11 0 0 0 4 3 12 2 1 2 1 2 2 1 1 1 0 0   4 2 8 Pos Pos Pos 
MN12 0 0 0 4 3 12 2 2 4 0 0 0 3 1 3 0 0 Pos 4 1 4 Pos Pos Pos 
MN13 0 0 0 4 3 12 2 2 4 0 1 0 2 2 4 0 0   4 3 12 Pos Pos Neg 
MN14 0 1 0 4 3 12 2 3 6 3 2 6 3 2 6 0 0 Pos 2 1 2 Pos Pos Pos 
MN15 1 1 1 4 3 12 3 2 6 2 1 2 3 2 6 0 0   4 2 8 Pos Pos Neg 
MN16 2 2 4 4 3 12 2 3 6 4 3 12 4 3 12 0 0 Pos 2 1 2 Pos Pos Pos 
MN17 1 2 2 4 3 12 3 3 9 1 2 2 4 3 12 0 0   4 3 12 Pos Pos Pos 
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Appendix 3: Cohort 2 (Mutation positive) Morphological features 
 
CASE G AGE SITE GD CONFIG PERF 
ASSOC 
POLYP TYPE GRADE TIL CROHNS TM T N M 
 
STAGE 
MP18 M 36 RIGHTX2 25,30 ULCERATED NO YES MUCINOUS    NO YES E 4 0 X 2 
MP19 M 44 RIGHT 70 EXOPHYTIC NO YES MUCINOUS    NO YES E 4 2 X 3 
MP20 M 47 RECTUM 40 ULCER NO NO MUCINOUS    NO YES If 2 2 X 3 
MP21 M 50 RIGHT 60 ULCER NO NO ADENO LOW NO NO E 3 1 X 3 
MP22 F 40 RIGHTx2 40,30 
ANN CONSTR & 
POLYPOID YES YES ADENO + MC LOW NO NO E 4 2 X 3 
MP23 F 73 RIGHT 16 EXOPHYTIC NO YES ADENO LOW YES YES E 2 0 X 1 
MP24 F 46 
RIGHT and 
LEFT 65,110 ANN CONSTR NO YES ADENO + MC LOW YES NO E 3 0 X 2 
MP25 M 41 RIGHT 16 EXOPHYTIC YES NO SIGNET RING   NO YES E 4 2 X 3 
MP26 M 35 RIGHT 60 ANN CONSTR NO NO ADENO LOW NO YES E 3 0 X 2 
MP27 M 29 LEFT 85 ULCERATED YES NO MEDULLARY    YES NO E 4 2 X 3 
MP28 M 45 RIGHT 60 ULCERATED NO NO ADENO LOW YES YES E 3 0 X 2 
MP29 F 30 RIGHT 78 EXOPHYTIC YES NO ADENO + MC LOW NO NO E 4 1 X 3 
MP30 F 46 RIGHT 65 EXOPHYTIC NO NO ADENO LOW NO NO E 3 0 X 2 
MP31 F 30 RIGHT 100 EXOPHYTIC NO NO ADENO + MC LOW NO NO E 3 0 X 2 
MP32 F 50 LEFT 57 ANN CONSTR NO NO MUCINOUS     YES YES E 3 1 X 3 
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Appendix 4: Cohort 2 (Mutation positive) Immunohistochemical and gene mutation results  
 
CASE p21 P27 
CYCLIN 
D1 
CYCLIN 
E p53 c-myc MMP7 MLH1 MSH6 MSH2 MUTATION 
  P I HS P I HS P I HS P I HS P I HS P I CYT P I HS         
MP18 0 0 0 4 2 8 1 2 2 0 0 0 1 1 1 0 0 
 
4 3 12 Neg Neg Pos MLH1 1528C>T 
MP19 0 2 0 3 2 6 3 2 6 2 2 4 2 3 6 0 0 Pos 4 2 8 Neg Pos Pos MLH1 1528C>T 
MP20 4 3 12 4 3 12 3 3 9 2 2 4 4 3 12 0 0 
 
3 2 6 Neg Neg Neg MLH1 1528C>T 
MP21 0 0 0 4 3 12 3 3 9 1 2 2 3 3 9 0 0 
 
4 2 8 Neg Pos Pos MLH1 1528C>T 
MP22 0 0 0 4 2 8 2 1 2 0 0 0 4 3 12 0 0 Pos 4 2 8 Pos Neg Neg 
MSH2 EXON7 del CT AT 
1219 
MP23 2 2 4 4 3 12 3 2 6 3 2 6 3 2 6 0 0 Pos 4 3 12 Neg Pos Pos MLH1 1528C>T 
MP24 0 0 0 4 3 12 4 2 8 2 2 4 0 0 0 0 0 
 
3 1 3 Neg Pos Pos MLH1 1528C>T 
MP25 0 0 0 4 2 8 1 1 1 1 1 1 2 2 4 0 0 
 
3 1 3 Pos Neg Neg 
MSH2 EXON3 del TC AT 
387 
MP26 0 0 0 4 3 12 2 1 2 3 1 3 3 3 9 0 0 
 
2 1 2 Neg Pos Pos MLH1 1528C>T 
MP27 0 0 0 4 2 8 2 2 4 2 2 4 3 3 9 0 0 Pos 4 3 12 Neg Neg Pos MLH1 1528C>T 
MP28 0 0 0 4 3 12 1 2 2 2 1 2 4 3 12 0 0 Pos 4 2 8 Neg Neg Pos MLH1 1528C>T 
MP29 0 0 0 4 3 12 3 3 9 3 2 6 3 2 6 0 0 Pos 4 3 12 Neg Pos Pos MLH1 1528C>T 
MP30 0 0 0 2 2 4 3 2 6 2 2 4 1 2 2 0 0 Pos 4 2 8 Neg Pos Pos MLH1 1528C>T 
MP31 0 0 0 4 3 12 3 3 9 3 3 9 2 2 4 0 0 Pos 4 1 4 Neg Pos Pos MLH1 1528C>T 
MP32 0 0 0 3 3 9 3 3 9 1 1 1 1 2 2 0 0 Pos 4 3 12 Neg Pos Pos MLH1 1528C>T 
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Appendix 5: Cohort 3 (Sporadic) Morphological features 
CASE G AGE SITE GD CONFIG PERF 
ASSOC 
POLYP TYPE GRADE TIL CROHNS TM T N M STAGE 
                                  
S33 F 53 RECTUM 30 ULCERATED NO NO ADENO LOW NO NO E 3 1 X 3 
S34 M 83 RECTUM 48 UNKNOWN NO NO ADENO LOW NO NO If 3 2 X 3 
S35 F 78 RECTUM 48 EXOPHYTIC NO NO ADENO LOW NO YES If 2 0 X 1 
S36 F 80 RIGHT 45 EXOPHYTIC NO YES MEDULLARY   YES NO E 3 1 X 3 
S37 F 73 RIGHT 50 EXOPHYTIC YES NO ADENO+MC LOW NO YES E 4 0 X 2 
S38 M 59 LEFT 90 ANN,CONSTR NO NO ADENO LOW NO YES If 3 0 X 2 
S39 M 80 RIGHT 60 ANN,CONSTR NO YES SIGNET RING   NO NO If 3 2 X 3 
S40 M 72 RECTUM 65 ANN,CONSTR NO NO MUCINOUS    NO NO If 3 0 X 2 
S41 M 65 RECTUM 52 EXOPHYTIC NO NO ADENO LOW NO NO If 3 0 X 2 
S42 F 65 LEFT 55 EXOPHYTIC YES NO ADENO LOW NO NO E 4 0 X 2 
S43 F 63 RIGHT 70 EXOPHYTIC NO NO MUCINOUS    NO NO If 3 1 X 3 
S44 F 60 RECTUM 25 ANN,CONSTR YES YES  ADENO LOW NO NO If 3 0 X 2 
S45 M 70 RIGHT 45 UNKNOWN NO NO ADENO LOW NO NO If 3 2 X 3 
S46 M 64 RECTUM 85 ANN,CONSTR NO NO ADENO LOW NO NO E 3 1 X 3 
S47 M 65 LEFT 55 EXOPHYTIC NO NO ADENO LOW NO YES If 3 1 X 3 
S48 M 80 RECTUM 30 ULCERATED NO NO ADENO LOW NO YES E 2 0 X 1 
S49 M 59 RIGHT 59 UNKNOWN YES NO ADENO LOW NO NO If 4 1 X 3 
S50 M 73 RIGHT 50 EXOPHYTIC YES NO ADENO+MC LOW NO NO If 4 0 X 2 
S51 M 64 RIGHT 65 EXOPHYTIC NO NO ADENO+MC LOW NO YES E 2 0 X 1 
S52 F 81 RIGHT 40 EXOPHYTIC NO NO ADENO LOW NO YES E 3 0 X 2 
S53 F 60 LEFT 90 ULCERATED NO NO ADENO HIGH NO NO If 3 2 X 3 
S54 M 73 RIGHT 73 UNKNOWN YES NO ADENO LOW NO YES If 4 0 X 2 
S55 F 64 RECTUM 39 ULCERATED NO NO ADENO+MC LOW NO NO If 3 1 X 3 
S56 F 62 RIGHT 105 UNKNOWN YES NO MUCINOUS    NO YES E 4 1 1 4 
S57 M 53 RIGHT 25 ULCERATED YES NO ADENO LOW NO YES E 4 1 X 3 
S58 M 57 RIGHT 110 EXOPHYTIC NO YES ADENO LOW NO NO If 3 1 X 3 
S59 F 61 RIGHT 60 UNKNOWN NO NO SERRATED+MC   NO YES E 2 0 X 1 
S60 F 59 RIGHT 90 EXOPHYTIC NO NO ADENO LOW YES YES E 3 0 X 2 
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Appendix 6: Cohort 3 (Sporadic) Immunohistochemical results 
CASE P21 P27 CYCLIN D1 CYCLIN E P53 c-myc MMP7 MLH1 MSH6 MSH2 
  P I HS P I HS P I HS P I HS P I HS P I CYT P I HS       
S33 0 0 0 4 2 8 0 0 0 1 1 1 4 3 12 0 0   4 2 8 Pos Pos Pos 
S34 0 0 0 4 3 12 0 0 0 3 2 6 4 3 12 0 0 Pos 4 1 4 Pos Pos Pos 
S35 0 0 0 3 3 9 0 0 0 0 0 0 4 3 12 0 0   4 2 8 Pos IN IN 
S36 0 0 0 3 2 6 3 2 6 2 2 4 1 1 1 0 0   4 2 8 Neg Pos Pos 
S37 0 0 0 4 3 12 0 0 0 0 1 0 0 0 0 0 0   4 2 8 Pos Pos Pos 
S38 0 0 0 4 3 12 0 1 0 0 0 0 4 3 12 0 0 Pos 4 1 4 Pos Pos Pos 
S39 0 0 0 4 3 12 0 2 0 0 0 0 0 2 0 0 0   4 2 8 Neg Neg Pos 
S40 1 1 1 4 3 12 2 2 4 0 1 0 3 2 6 0 0   4 3 12 Pos Pos Pos 
S41 0 0 0 4 3 12 2 1 2 0 0 0 4 3 12 0 0 Pos 2 1 2 Pos Pos Pos 
S42 0 0 0 3 3 9 3 3 9 0 0 0 2 3 6 0 0 Pos 4 1 4 Pos Pos Pos 
S43 2 3 6 4 3 12 4 3 12 0 0 0 2 3 6 0 0   4 2 8 Neg Pos Pos 
S44 0 0 0 3 3 9 2 3 6 2 2 4 4 3 12 0 0 Pos 4 2 8 Pos Pos Pos 
S45 0 0 0 3 3 9 0 0 0 0 0 0 0 0 0 0 0 Pos 2 1 2 Pos Pos Pos 
S46 0 1 0 4 3 12 3 2 6 1 1 1 4 3 12 0 0   4 1 4 Pos Pos Pos 
S47 0 0 0 3 2 6 2 2 4 0 1 0 4 3 12 0 0   4 2 8 Pos Pos Pos 
S48 0 0 0 3 3 9 1 2 2 0 0 0 0 0 0 0 0 Pos 4 2 8 Pos Neg IN 
S49 0 0 0 2 2 4 0 0 0 0 0 0 4 3 12 0 0 Pos 4 2 8 Pos Pos Pos 
S50 0 0 0 3 3 9 2 2 4 0 0 0 4 3 12 0 0 Pos 4 1 4 Pos Pos Pos 
S51 0 0 0 3 2 6 1 2 2 0 0 0 4 3 12 0 0 Pos 4 2 8 Pos Pos Pos 
S52 0 0 0 3 2 6 3 2 6 2 1 2 4 3 12 0 0 Pos 4 2 8 Pos Pos Pos 
S53 0 0 0 4 3 12 2 2 4 1 1 1 0 0 0 0 0 Pos 4 2 8 Pos Pos Pos 
S54 0 0 0 4 3 12 1 1 1 0 0 0 0 0 0 0 0 Pos 4 3 12 Pos Pos Pos 
S55 0 0 0 4 3 12 1 1 1 1 2 2 4 3 12 0 0   4 2 8 Pos Pos Pos 
S56 0 0 0 3 2 6 1 2 2 0 0 0 0 0 0 0 0   3 2 6 Neg Pos Pos 
S57 1 1 1 3 2 6 3 3 9 3 2 6 0 0 0 0 0 Pos 4 1 4 Pos Pos Pos 
S58 0 0 0 3 3 9 3 2 6 0 1 0 2 2 4 0 0 Pos 4 2 8 Pos IN Pos 
S59 0 0 0 4 3 12 4 3 12 1 2 2 0 2 0 0 0   4 1 4 Neg Neg Neg 
S60 0 0 0 3 2 6 1 1 1 1 1 1 0 0 0 0 0 Pos 4 3 12 Pos Pos Pos 
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